



Rec'd PCT/PC 24 JAN 2005
PCT/GB 2003 / 003171



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 15 AUG 2003
WIPO PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed


Stephen Hordley

Dated 7 August 2003


Best Available Copy

Patents

Patents Act 1977
(Rule 16)



The
Patent
Office



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

100804

2. Patent application number

(The Patent Office will fill in this part)

0217433.2

12/7 JUL 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
S-151 85 Sodertalje
Sweden

Patents ADP number (if you know it)

7822448003

FS

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (if you have one)

Lucy Clare Padget

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG

Patents ADP number (if you know it)

7822471002

FS

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 55

Claim(s) 3

Abstract 1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(*please specify*)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

Authorised Signatory

26/07/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer C Bennett - 01625 230148

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

CHEMICAL COMPOUNDS

This invention relates to chemical compounds, or pharmaceutically acceptable salts thereof. These compounds possess human 11- β -hydroxysteroid dehydrogenase type 1 enzyme (11 β HSD1) inhibitory activity and accordingly have value in the treatment of disease states including metabolic syndrome and are useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit 11 β HSD1 in a warm-blooded animal, such as man.

10 Glucocorticoids (cortisol in man, corticosterone in rodents) are counter regulatory hormones i.e. they oppose the actions of insulin (Dallman MF, Strack AM, Akana SF et al. 1993; Front Neuroendocrinol 14, 303-347). They regulate the expression of hepatic enzymes involved in gluconeogenesis and increase substrate supply by releasing glycerol from adipose tissue (increased lipolysis) and amino acids from muscle (decreased protein synthesis and
15 increased protein degradation). Glucocorticoids are also important in the differentiation of pre-adipocytes into mature adipocytes which are able to store triglycerides (Bujalska IJ et al. 1999; Endocrinology 140, 3188-3196). This may be critical in disease states where glucocorticoids induced by "stress" are associated with central obesity which itself is a strong risk factor for type 2 diabetes, hypertension and cardiovascular disease (Bjorntorp P &
20 Rosmond R 2000; Int. J. Obesity 24, S80-S85)

It is now well established that glucocorticoid activity is controlled not simply by secretion of cortisol but also at the tissue level by intracellular interconversion of active cortisol and inactive cortisone by the 11-beta hydroxysteroid dehydrogenases, 11 β HSD1 (which activates cortisone) and 11 β HSD2 (which inactivates cortisol) (Sandeep TC & Walker
25 BR 2001 Trends in Endocrinol & Metab. 12, 446-453). That this mechanism may be important in man was initially shown using carbenoxolone (an anti-ulcer drug which inhibits both 11 β HSD1 and 2) treatment which (Walker BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159) leads to increased insulin sensitivity indicating that 11 β HSD1 may well be regulating the effects of insulin by decreasing tissue levels of active glucocorticoids (Walker
30 BR et al. 1995; J. Clin. Endocrinol. Metab. 80, 3155-3159).

Clinically, Cushing's syndrome is associated with cortisol excess which in turn is associated with glucose intolerance, central obesity (caused by stimulation of pre-adipocyte differentiation in this depot), dyslipidaemia and hypertension. Cushing's syndrome shows a

number of clear parallels with metabolic syndrome. Even though the metabolic syndrome is not generally associated with excess circulating cortisol levels (Jessop DS et al. 2001; J. Clin. Endocrinol. Metab. 86, 4109-4114) abnormally high 11 β HSD1 activity within tissues would be expected to have the same effect. In obese men it was shown that despite having similar or
5 lower plasma cortisol levels than lean controls, 11 β HSD1 activity in subcutaneous fat was greatly enhanced (Rask E et al. 2001; J. Clin. Endocrinol. Metab. 1418-1421). Furthermore, the central fat, associated with the metabolic syndrome expresses much higher levels of 11 β HSD1 activity than subcutaneous fat (Bujalska IJ et al. 1997; Lancet 349, 1210-1213). Thus there appears to be a link between glucocorticoids, 11 β HSD1 and the metabolic
10 syndrome.

11 β HSD1 knock-out mice show attenuated glucocorticoid-induced activation of gluconeogenic enzymes in response to fasting and lower plasma glucose levels in response to stress or obesity (Kotelevtsev Y et al. 1997; Proc. Natl. Acad. Sci USA 94, 14924-14929) indicating the utility of inhibition of 11 β HSD1 in lowering of plasma glucose and hepatic
15 glucose output in type 2 diabetes. Furthermore, these mice express an anti-atherogenic lipoprotein profile, having low triglycerides, increased HDL cholesterol and increased apolipoprotein AI levels. (Morton NM et al. 2001; J. Biol. Chem. 276, 41293-41300). This phenotype is due to an increased hepatic expression of enzymes of fat catabolism and PPAR α . Again this indicates the utility of 11 β HSD1 inhibition in treatment of the
20 dyslipidaemia of the metabolic syndrome.

The most convincing demonstration of a link between the metabolic syndrome and 11 β HSD1 comes from recent studies of transgenic mice over-expressing 11 β HSD1 (Masuzaki H et al. 2001; Science 294, 2166-2170). When expressed under the control of an adipose specific promoter, 11 β HSD1 transgenic mice have high adipose levels of
25 corticosterone, central obesity, insulin resistant diabetes, hyperlipidaemia and hyperphagia. Most importantly, the increased levels of 11 β HSD1 activity in the fat of these mice are similar to those seen in obese subjects. Hepatic 11 β HSD1 activity and plasma corticosterone levels were normal, however, hepatic portal vein levels of corticosterone were increased 3 fold and it is thought that this is the cause of the metabolic effects in liver.

30 Overall it is now clear that the complete metabolic syndrome can be mimicked in mice simply by overexpressing 11 β HSD1 in fat alone at levels similar to those in obese man.

11 β HSD1 tissue distribution is widespread and overlapping with that of the glucocorticoid receptor. Thus, 11 β HSD1 inhibition could potentially oppose the effects of glucocorticoids in a number of physiological/pathological roles. 11 β HSD1 is present in human skeletal muscle and glucocorticoid opposition to the anabolic effects of insulin on protein turnover and glucose metabolism are well documented (Whorwood CB et al. 2001; J. Clin. Endocrinol. Metab. 86, 2296-2308). Skeletal muscle must therefore be an important target for 11 β HSD1 based therapy.

Glucocorticoids also decrease insulin secretion and this could exacerbate the effects of glucocorticoid induced insulin resistance. Pancreatic islets express 11 β HSD1 and carbenoxolone can inhibit the effects of 11-dehydrocorticosterone on insulin release (Davani B et al. 2000; J. Biol. Chem. 275, 34841-34844). Thus in treatment of diabetes 11 β HSD1 inhibitors may not only act at the tissue level on insulin resistance but also increase insulin secretion itself.

Skeletal development and bone function is also regulated by glucocorticoid action. 11 β HSD1 is present in human bone osteoclasts and osteoblasts and treatment of healthy volunteers with carbenoxolone showed a decrease in bone resorption markers with no change in bone formation markers (Cooper MS et al 2000; Bone 27, 375-381). Inhibition of 11 β HSD1 activity in bone could be used as a protective mechanism in treatment of osteoporosis.

Glucocorticoids may also be involved in diseases of the eye such as glaucoma. 11 β HSD1 has been shown to affect intraocular pressure in man and inhibition of 11 β HSD1 may be expected to alleviate the increased intraocular pressure associated with glaucoma (Rauz S et al. 2001; Investigative Ophthalmology & Visual Science 42, 2037-2042).

There appears to be a convincing link between 11 β HSD1 and the metabolic syndrome both in rodents and in humans. Evidence suggests that a drug which specifically inhibits 11 β HSD1 in type 2 obese diabetic patients will lower blood glucose by reducing hepatic gluconeogenesis, reduce central obesity, improve the atherogenic lipoprotein phenotype, lower blood pressure and reduce insulin resistance. Insulin effects in muscle will be enhanced and insulin secretion from the beta cells of the islet may also be increased.

Currently there are two main recognised definitions of metabolic syndrome.

1) The Adult Treatment Panel (ATP III 2001 JMA) definition of metabolic syndrome indicates that it is present if the patient has three or more of the following symptoms:

- Waist measuring at least 40 inches (102 cm) for men, 35 inches (88 cm) for women;


- Serum triglyceride levels of at least 150 mg/dl (1.69 mmol/l);
- HDL cholesterol levels of less than 40 mg/dl (1.04 mmol/l) in men, less than 50 mg/dl (1.29 mmol/l) in women;
- Blood pressure of at least 135/80 mm Hg; and / or
- 5 ➤ Blood sugar (serum glucose) of at least 110 mg/dl (6.1 mmol/l).

2) The WHO consultation has recommended the following definition which does not imply causal relationships and is suggested as a working definition to be improved upon in due course:

- The patient has at least one of the following conditions: glucose intolerance, impaired glucose tolerance (IGT) or diabetes mellitus and/or insulin resistance; together with
- 10 two or more of the following:
 - Raised Arterial Pressure;
 - Raised plasma triglycerides
 - Central Obesity
 - 15 ➤ Microalbuminuria

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective 11 β HSD1 inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome.

Accordingly there is provided the use of a compound of formula (I):



(I)

wherein:

Ring A is selected from aryl or heteroaryl;

- R¹** is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, N-(C₁₋₄alkyl)sulphamoyl, N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; or two R¹ on
- 30 adjacent carbons may form an oxyC₁₋₄alkoxy group; wherein R¹ may be optionally substituted

on carbon by one or more groups selected from R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^8 ;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2 , R^3 , R^4 and R^5 are independently selected from hydrogen, hydroxy, amino, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclylC₁₋₄alkyl, heterocyclylC₁₋₄alkyl; wherein R^2 , R^3 , R^4 and R^5 may be independently optionally substituted on carbon by one or more groups selected from R^9 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{10} ;

10 X is $-CR^{11}R^{12}-$, $-S(O)_a-$, $-O-$, $-NR^{13}-$, $-C(O)-$, $-C(O)NR^{14}-$, $-NR^{15}C(O)-$, $-SO_2NR^{16}-$ or $-NR^{16}SO_2-$; wherein a is 0 to 2;

q is 0 or 1;

p is 0 or 1;

15 **Ring B** is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; wherein R^6 may be optionally substituted on carbon by one or more groups selected from R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{19} ;

m is 0-3; wherein the values of R^6 may be the same or different;

Y is $-S(O)_a-$, $-O-$, $-NR^{20}-$, $-C(O)-$, $-C(O)NR^{21}-$, $-NR^{22}C(O)-$ or $-SO_2NR^{23}-$; wherein a is 0 to 2;

30 R^7 , R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl,

N-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R⁷, R⁹ and R¹⁸ may be independently optionally substituted on carbon by one or more R²⁶;

R¹¹ and R¹² are independently selected from hydrogen, hydroxy, amino, cyano,

5 C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl carbocyclylC₁₋₄alkyl, heterocyclylC₁₋₄alkyl; wherein R⁹ and R¹⁰ may be independently optionally substituted on carbon by one or more groups selected from R²⁴; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁵;

10 R²⁴ is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl
15 and C₁₋₄alkylsulphonylamino;

R⁸, R¹⁰, R¹⁷, R¹⁹ and R²⁵ are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkylsulphonyl, C₁₋₄alkoxycarbonyl, carbamoyl, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R¹³, R¹⁴, R¹⁵, R¹⁶, R²⁰, R²¹, R²² and R²³ are independently selected from hydrogen,
20 phenyl and C₁₋₄alkyl;

R²⁶ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl,

25 *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;
or a pharmaceutically acceptable salt thereof;

30 in the manufacture of a medicament for use in the inhibition of 11βHSD1.

According to a further feature of the invention there is provided a compound of formula (Ia):



wherein:

Ring A is selected from furanyl, thienyl or pyridyl;

- 5 **R¹** is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, N-(C₁₋₄alkyl)sulphamoyl, N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl, 10 heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; or two R¹ on adjacent carbons may form an oxyC₁₋₄alkoxy group; wherein R¹ may be optionally substituted on carbon by one or more groups selected from R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁸;

n is 0-3; wherein the values of R¹ may be the same or different;

- 15 **R²** is selected from amino, C₁₋₃alkoxy, N-(C₁₋₃alkyl)amino; wherein R² may be optionally substituted on carbon by one or more groups selected from R⁹;

Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

- 20 **R⁶** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, 25 N-(C₁₋₄alkyl)sulphamoyl, N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R⁶ may be optionally substituted on carbon by one or more groups selected from R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

m is 0-3; wherein the values of R⁶ may be the same or different;


- 30 **Y** is -S(O)_a-, -O-, -NR²⁰-, -C(O)-, -C(O)NR²¹-, -NR²²C(O)- or -SO₂NR²³-; wherein a is 0 to 2;

R^7 , R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, 5 N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl;

R^8 , R^{17} and R^{19} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, 10 N,N -(C_{1-4} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R^{20} , R^{21} , R^{22} and R^{23} are independently selected from hydrogen and C_{1-4} alkyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (α -methoxybenzyl)-(pyrid-4-yl)-ketone, (α -aminobenzyl)-(pyrid-3-yl)-ketone, [1-(fur-2-yl)-1-(ethoxy)methyl]-(fur-2-yl)-ketone or [1- 15 (fur-2-yl)-1-(methoxy)methyl]-(fur-2-yl)-ketone.

According to a further feature of the invention there is provided a compound of formula (Ib):



20 wherein:

Ring A is thiazolyl;

R^1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, 25 N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; or two R^1 on adjacent carbons may form an oxyC₁₋₄alkoxy group; wherein R^1 may be optionally substituted on carbon by one or more groups selected from R^7 ; and wherein if said heterocyclyl contains 30 an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^8 ;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2 is selected from hydroxy, amino, C_{1-3} alkoxy, N -(C_{1-3} alkyl)amino; wherein R^2 may be optionally substituted on carbon by one or more groups selected from R^9 ;

Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl
5 contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino,
10 N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R^6 may be optionally substituted on carbon by one or more groups selected from R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen
15 may be optionally substituted by a group selected from R^{19} ;

m is 0-3; wherein the values of R^6 may be the same or different;


Y is -S(O)_a-, -O-, -NR²⁰-, -C(O)-, -C(O)NR²¹-, -NR²²C(O)- or -SO₂NR²³-; wherein a is 0 to 2;

R^7 , R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino,
20 carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl
25 and heterocyclyl;

R^8 , R^{17} and R^{19} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R^{20} , R^{21} , R^{22} and R^{23} are independently selected from hydrogen and C_{1-4} alkyl;
30 or a pharmaceutically acceptable salt thereof.

According to a further feature of the invention there is provided a compound of formula (Ic):



wherein:

Ring A is selected from furyl, thienyl, thiazolyl and pyridyl;

- 5 **R¹** is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, N-(C₁₋₄alkyl)sulphamoyl, N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; or two R¹ on adjacent carbons may form an oxyC₁₋₄alkoxy group; wherein R¹ may be optionally substituted on carbon by one or more groups selected from R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁸;

n is 0-3; wherein the values of R¹ may be the same or different;

- 15 **R²** is selected from 3-6 membered aryl or carbon linked 3-6 membered heteroaryl; wherein R² may be independently optionally substituted on carbon by one or more groups selected from R⁹; and wherein if said heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁰;

- Ring B** is 3-6 membered aryl or a carbon linked 3-6 membered heteroaryl; wherein if said heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

- R⁶** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, N-(C₁₋₄alkyl)carbamoyl, N,N-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, N-(C₁₋₄alkyl)sulphamoyl, N,N-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R⁶ may be optionally substituted on carbon by one or more groups selected from R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

m is 0-3; wherein the values of R⁶ may be the same or different;

Y is $-S(O)_a-$, $-O-$, $-NR^{20}-$, $-C(O)-$, $-C(O)NR^{21}-$, $-NR^{22}C(O)-$ or $-SO_2NR^{23}-$; wherein a is 0 to 2;


R^7 , R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, $N-(C_{1-4}alkyl)amino$, $N,N-(C_{1-4}alkyl)_2amino$, $C_{1-4}alkanoylamino$, $N-(C_{1-4}alkyl)carbamoyl$, $N,N-(C_{1-4}alkyl)_2carbamoyl$, $C_{1-4}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-4}alkoxycarbonyl$, $N-(C_{1-4}alkyl)sulphamoyl$, $N,N-(C_{1-4}alkyl)_2sulphamoyl$, $C_{1-4}alkylsulphonylamino$, carbocyclyl and heterocyclyl;

R^8 , R^{10} , R^{17} and R^{19} are independently selected from $C_{1-4}alkyl$, $C_{1-4}alkanoyl$, $C_{1-4}alkylsulphonyl$, $C_{1-4}alkoxycarbonyl$, carbamoyl, $N-(C_{1-4}alkyl)carbamoyl$, $N,N-(C_{1-4}alkyl)carbamoyl$, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R^{20} , R^{21} , R^{22} and R^{23} are independently selected from hydrogen and $C_{1-4}alkyl$; or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not [1-(pyrazin-2-yl)-2-(2-fluorophenyl)ethyl]-(fur-2-yl)-ketone, [1-(pyrazin-2-yl)-2-(4-chlorophenyl)ethyl]-(fur-2-yl)-ketone, [2-(pyridin-3-yl)-1-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(fur-2-yl)-1-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(4-nitrophenyl)-1-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(thien-2-yl)-1-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone, [2-(phenyl)-1-(2,4-dichlorophenyl)ethyl]-(pyrid-3-yl)-ketone or [2-(4-chlorophenyl)-1-(pyrazin-2-yl)ethyl]-(pyrid-3-yl)-ketone.

According to a further feature of the invention there is provided a compound of formula (Id):



(Id)

wherein:

Ring A is thiazolyl;

R^1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, $C_{1-4}alkyl$, $C_{2-4}alkenyl$, $C_{2-4}alkynyl$, $C_{1-4}alkoxy$, $C_{1-4}alkanoyl$, $C_{1-4}alkanoyloxy$, $N-(C_{1-4}alkyl)amino$, $N,N-(C_{1-4}alkyl)_2amino$, $C_{1-4}alkanoylamino$, $N-(C_{1-4}alkyl)carbamoyl$, $N,N-(C_{1-4}alkyl)_2carbamoyl$, $C_{1-4}alkylS(O)_a$ wherein a is 0 to 2, $C_{1-4}alkoxycarbonyl$,

N-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; or two R¹ on adjacent carbons may form an oxyC₁₋₄alkoxy group; wherein R¹ may be optionally substituted on carbon by one or more groups selected from R⁷; and wherein if said heterocyclyl contains

5 an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁸;

n is 0-3; wherein the values of R¹ may be the same or different;

Ring B is 3-6 membered aryl or a 3-6 membered heteroaryl; wherein if said heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁷;

10 R⁶ is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl,

15 *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R⁶ may be optionally substituted on carbon by one or more groups selected from R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁹;

m is 0-3; wherein the values of R⁶ may be the same or different;

20 Y is -S(O)_a-, -O-, -NR²⁰-, -C(O)-, -C(O)NR²¹-, -NR²²C(O)- or -SO₂NR²³-; wherein a is 0 to 2;

R⁷ and R¹⁸ are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, *N*-(C₁₋₄alkyl)amino,

25 *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkanoylamino, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)₂carbamoyl, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkoxycarbonyl, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-(C₁₋₄alkyl)₂sulphamoyl, C₁₋₄alkylsulphonylamino, carbocyclyl and heterocyclyl;


R⁸, R¹⁷ and R¹⁹ are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl,

30 C₁₋₄alkylsulphonyl, C₁₋₄alkoxycarbonyl, carbamoyl, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R²⁰, R²¹, R²² and R²³ are independently selected from hydrogen and C₁₋₄alkyl; or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not (phenethyl)-(5-aminothiazol-4-yl)-ketone.

According to a further feature of the invention there is provided a compound of formula (Ie):



(Ie)

wherein:

G is O or S;

R^1 is selected from fluoro, chloro, bromo, sulphamoyl, methyl, methoxy, ethoxy, acetyl or thiomethyl;

n is 0-3; wherein the values of R^1 may be the same or different;

Ring B is 3-6 membered aryl or a 3-6 membered carbon linked heteroaryl; wherein if said heteroaryl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R^6 may be optionally substituted on carbon by one or more groups selected from R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{19} ;


m is 0-3; wherein the values of R^6 may be the same or different;

R^{18} is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl;

R^{17} and R^{19} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof;

- 5 with the proviso that said compound is not (2,5-dimethylthien-3-yl)-(2,5-dimethylthien-3-ylmethyl)-ketone; (2,5-dichlorothien-3-yl)-(benzyl)-ketone; (2,4,5-trichlorothien-3-yl)-(benzyl)-ketone; (4-bromothien-3-yl)-(2-nitrobenzyl)-ketone; (2-methylfur-3-yl)-(benzyl)-ketone; or (2,5-dimethylthien-3-yl)-(5-chlorothien-2-ylmethyl)-ketone.

According to a further feature of the invention there is provided a compound of
10 formula (If):



wherein:

- R^1 is selected from fluoro, chloro, bromo, sulphamoyl, methyl, methoxy, ethoxy,
15 acetyl or thiomethyl;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2 is N -(C_{1-4} alkyl)amino; wherein R^2 may be optionally substituted on carbon by one or more groups selected from R^9 ;

- R^3 is selected from hydrogen or C_{1-4} alkyl; wherein R^3 may be optionally substituted
20 on carbon by one or more groups selected from R^9 ;

Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;


- R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl,
25 C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R^6 may be optionally substituted on carbon by one or more groups
30 selected from R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{19} ;

m is 0-3; wherein the values of R^6 may be the same or different;

R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino,
 5 N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl) $_2$ carbamoyl, C_{1-4} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl) $_2$ sulphamoyl and C_{1-4} alkylsulphonylamino;

R^{17} and R^{19} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl,
 10 N,N -(C_{1-4} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof; with the proviso that said compound is not (4-methoxyphenyl)-[α -(1-hydroxyprop-2-ylamino)-4-methoxybenzyl]-ketone; (4-methoxyphenyl)-[α -(butylamino)-4-methoxybenzyl]-ketone; (4-methoxyphenyl)-[α -(ethylamino)benzyl]-ketone; (4-methoxyphenyl)-[α -(1-
 15 hydroxybut-2-ylamino)benzyl]-ketone; (4-methoxyphenyl)-[α -(1-hydroxybut-2-ylamino)-4-methoxybenzyl]-ketone; [3,4-dimethoxy-6-(methoxycarbonylmethyl)phenyl]-[α -(methylamino)benzyl]-ketone; (4-methoxyphenyl)-[α -(butylamino)benzyl]-ketone; (4-methoxyphenyl)-[α -(1-hydroxyethylamino)-4-methoxybenzyl]-ketone; or (4-methoxyphenyl)-[α -(1-hydroxyethylamino)benzyl]-ketone.

20 According to a further feature of the invention there is provided a compound of formula (Ig):



(Ig)

wherein:

- 25 **Ring A** is selected from aryl or heteroaryl;
 R^1 is selected from fluoro, chloro or methyl;
 R^2 is C_{1-4} alkoxy; wherein R^2 may be optionally substituted on carbon by one or more groups selected from R^9 ;
 R^3 is selected from hydrogen or C_{1-4} alkyl; wherein R^3 may be optionally substituted
 30 on carbon by one or more groups selected from R^9 ;

Ring B is carbocyclyl or a carbon linked heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl; wherein R^6 may be optionally substituted on carbon by one or more groups selected from R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{19} ;

m is 0-3; wherein the values of R^6 may be the same or different;

R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl and heterocyclyl;

R^{17} and R^{19} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not (4-methylphenyl)-(α-methoxybenzyl)-ketone; (4-chlorophenyl)-(α-ethoxy-2-chlorobenzyl)-ketone; (4-chlorophenyl)-[1-(3-nitroimidazo[1,2-a]pyridin-8-yl)-1-(methoxy)methyl]-ketone; (4-methylphenyl)-(α-methoxy-α-methylbenzyl)-ketone; (2,4,6-trimethylphenyl)-(α-methoxy-α-methyl-2,4,6-trimethylbenzyl)-ketone; (2,4-dichlorophenyl)-(α-methoxybenzyl)-ketone; (4-fluorophenyl)-(α-methoxybenzyl)-ketone; (4-methylphenyl)-(α-methoxy-4-methylbenzyl)-ketone; (4-methylphenyl)-(α-*t*-butoxy-4-methylbenzyl)-ketone; (3-nitro-4-chlorophenyl)-(α-methoxy-3-nitro-4-chlorobenzyl)-ketone; (4-methylphenyl)-(α-but-2-yloxybenzyl)-ketone; (4-chlorophenyl)-(α-isopropoxy-4-chlorobenzyl)-ketone; (4-chlorophenyl)-(α-isopropoxybenzyl)-ketone; (4-methylphenyl)-(α-

isopropoxybenzyl)-ketone; (4-methylphenyl)-(α -isopropoxy-4-methylbenzyl)-ketone; (4-chlorophenyl)-(α -methoxybenzyl)-ketone; (4-chlorophenyl)-(α -methoxy-4-chlorobenzyl)-ketone; or (4-chlorophenyl)-(α -methoxy- α -methyl-4-chlorobenzyl)-ketone.

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C₁₋₄alkyl" includes propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals therefore "carbocyclylC₁₋₄alkyl" includes 1-carbocyclylpropyl, 2-carbocyclylethyl and 3-carbocyclylbutyl. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

"Heteroaryl" is a totally unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Suitably "heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 8 - 10 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Examples and suitable values of the term "heteroaryl" are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, indolyl, pyrimidyl, pyrazinyl, pyridazinyl, benzothienyl, pyridyl and quinolyl. Particularly "heteroaryl" refers to thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.

"3-6 Membered heteroaryl" is a totally unsaturated, mono or bicyclic ring containing 3-6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Suitably "3-6 membered heteroaryl" refers to a totally unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked. Examples and suitable values of the term "3-6 membered heteroaryl" are thienyl, furyl, thiazolyl, pyrazolyl, isoxazolyl, imidazolyl, pyrrolyl, thiadiazolyl, isothiazolyl, triazolyl, pyranyl, pyrimidyl, pyrazinyl, pyridazinyl and pyridyl.

Particularly "heteroaryl" refers to thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.

"Aryl" is a totally unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms. Suitably "aryl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "aryl" include phenyl or naphthyl. Particularly "aryl" is phenyl.

"3-6 Membered aryl" is a totally unsaturated, mono or bicyclic carbon ring that contains 3-6 atoms. Suitably "3-6 membered aryl" is a monocyclic ring containing 5 or 6 atoms. Suitable values for "3-6 membered aryl" include phenyl.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a $-CH_2-$ group can optionally be replaced by a $-C(O)-$ or a ring sulphur atom may be optionally oxidised to form the S-oxides. Preferably a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a $-CH_2-$ group can optionally be replaced by a $-C(O)-$ or a ring sulphur atom may be optionally oxidised to form S-oxide(s). Examples and suitable values of the term "heterocyclyl" are thienyl, piperidinyl, morpholinyl, furyl, thiazolyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phthalidyl, pyrazolyl, pyrazinyl, pyridazinyl, benzothienyl, benzimidazolyl, tetrahydrofuryl, [1,2,4]triazolo[4,3-a]pyrimidinyl, piperidinyl, indolyl, 1,3-benzodioxolyl and pyrrolidinyl.

A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a $-CH_2-$ group can optionally be replaced by a $-C(O)-$. Preferably "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. Particularly "carbocyclyl" is cyclohexyl, phenyl, naphthyl or 2-6-dioxocyclohexyl.

An example of " C_{1-4} alkanoyloxy" is acetoxy. Examples of " C_{1-4} alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of " C_{1-4} alkoxy" include methoxy, ethoxy and propoxy. Examples of " $oxyC_{1-4}alkoxy$ " include oxymethoxy, oxyethoxy and oxypropoxy. Examples of " C_{1-4} alkanoylamino" include formamido, acetamido and propionylamino. Examples of and " $C_{1-4}alkylS(O)_a$ " wherein *a* is 0

to 2" include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of and "C₁₋₄alkylsulphonyl" include mesyl and ethylsulphonyl.

Examples of "C₁₋₄alkanoyl" include C₁₋₃alkanoyl, propionyl and acetyl. Examples of

"N-(C₁₋₄alkyl)amino" include methylamino and ethylamino. Examples of

- 5 "N,N-(C₁₋₄alkyl)₂amino" include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino. Examples of "C₂₋₄alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C₂₋₄alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of "N-(C₁₋₄alkyl)sulphamoyl" are N-(C₁₋₃alkyl)sulphamoyl, N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C₁₋₄alkyl)₂sulphamoyl" are N,N-(dimethyl)sulphamoyl
- 10 and N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(C₁₋₄alkyl)carbamoyl" are methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(C₁₋₄alkyl)₂carbamoyl" are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C₁₋₄alkylsulphonylamino" are mesylamino and ethylsulphonylamino. Examples of "C₀₋₄alkylene" are a direct bond, methylene and ethylene.

- 15 A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is
- 20 sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

- 25 Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess 11 β HSD1 inhibitory activity.

- The invention relates to any and all tautomeric forms of the compounds of the formula
- 30 (I) that possess 11 β HSD1 inhibitory activity.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be

understood that the invention encompasses all such solvated forms which possess 11 β HSD1 inhibitory activity.

Particular values of variable groups are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or

5 hereinafter.

Ring A is selected from aryl.

Ring A is heteroaryl.

Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl.

10 Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl.

Ring A is selected from phenyl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl.

Ring A is phenyl substituted at the position para to the ketone.

15 R^1 is selected from halo, cyano, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkylS(O) $_a$ wherein a is 0, carbocyclyl, carbocyclyl C_{0-4} alkylene-Y- and heterocyclyl C_{0-4} alkylene-Y-; or two R^1 on adjacent carbons may form an oxy C_{1-4} alkoxy group; wherein R^1 may be optionally substituted on carbon by one or more groups selected from R^7 ;

20 Y is -S(O) $_a$ - or -O-; wherein a is 0 to 2; and

R^7 is halo.

R^1 is selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, *t*-butyl, trifluoromethyl, methoxy, ethoxy, butoxy, dimethylamino, methylthio, 4-chlorophenyl, benzyloxy, morpholinosulphonyl and tetrahydrofur-2-yloxy; or two R^1 on adjacent carbons

25 may form oxymethyleneoxy.

R^1 is selected from fluoro, chloro, bromo, cyano, methyl, trifluoromethyl, methoxy and ethoxy.

n is 0-2; wherein the values of R^1 may be the same or different.

n is 0-1.

30 n is 0.

n is 1.

R^2 , R^3 , R^4 and R^5 are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl) $_2$ amino, carbocyclyl, heterocyclyl,

carbocyclylC₁₋₄alkyl, heterocyclylC₁₋₄alkyl; wherein R², R³, R⁴ and R⁵ may be independently optionally substituted on carbon by one or more groups selected from R⁹;

R⁹ is selected from halo, nitro, cyano, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, C₁₋₄alkoxycarbonyl and carbocyclyl; wherein R⁹ may be optionally substituted on carbon by one or more R²⁶; wherein

R²⁶ is hydroxy.

R², R³, R⁴ and R⁵ are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, isobutoxy, cyanomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, N,N-dimethylaminomethyl, N,N-diethylaminomethyl, N,N-dipropylaminomethyl, N,N-diisopropylaminomethyl, 2-hydroxyethylaminomethyl, methylamino, ethylamino, propylamino, isopropylamino, 2-hydroxyethylamino, 2-(N,N-diethylamino)ethylamino, 3-(N,N-dimethylamino)propylamino, N,N-dipropylamino, phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, piperidin-1-yl, indol-1-yl, 1,3-benzodioxol-5-yl, benzyl, α -cyanobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 2-ethoxycarbonylbenzyl, 3-nitrobenzyl, 3-trifluoromethylbenzyl, 3-methoxycarbonylbenzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, 3-nitro-6-methoxybenzyl, benzylamino, phenethylaminopyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, morpholinomethyl, 5-nitrofur-2-ylmethyl, 2-methylthiazol-4-ylmethyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl.

R², R³, R⁴ and R⁵ are independently selected from hydrogen, hydroxy, amino, cyano, methyl, ethyl, propyl, isopropyl, ethoxy, cyanomethyl, methylamino, ethylamino, propylamino, isopropylamino, piperidin-1-yl, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, benzylamino, piperidin-1-ylmethyl, morpholinomethyl, 2-methylthiazol-4-ylmethyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl and pyrid-4-ylmethyl.

X is -S(O)_a-, -O-, -NR¹³-, -NR¹⁵C(O)-, -SO₂NR¹⁶- or -NR¹⁶SO₂-; wherein a is 0 or 2;

R¹³, R¹⁵ and R¹⁶ are independently selected from hydrogen, phenyl and C₁₋₄alkyl.

X is -S-, -S(O)₂-, -O-, -NH-, -NMe-, -NHC(O)-, -SO₂NMe- or -NPhSO₂-.

X is -S(O)₂-, -O-, -NH-, -NMe-, -NHC(O)-, -SO₂NMe- or -NPhSO₂-.

q is 0.

q is 1.

p is 0.

p is 1.

Ring B is carbocyclyl.

Ring B is heterocyclyl.

Ring B is phenyl, thienyl, piperidinyl, morpholinyl, naphthyl, 2,6-dioxocyclohexyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl, phthalidyl, pyrazinyl, pyridazinyl, benzimidazolyl or [1,2,4]triazolo[4,3-a]pyrimidinyl; wherein if said imidazolyl or morpholinyl is linked via a carbon it may be optionally substituted on the -NH- by a group selected from R¹⁷;

R¹⁷ is selected from C₁₋₄alkyl or benzyl.

10 Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin-1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, naphth-1-yl, naphth-2-yl, 2,6-dioxocyclohex-1-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, 1-methylimidazol-2-yl, 1,2,4-triazol-1-yl, thiomorpholino, coumarin-7-yl, pyrimidin-2-yl, phthalid-3-yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [1,2,4]triazolo[4,3-a]pyrimidin-5-yl.

15 Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin-1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, thiomorpholino, pyrimidin-2-yl, phthalid-3-yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [1,2,4]triazolo[4,3-a]pyrimidin-5-yl.

Ring B is phenyl substituted at the position para to -(CR⁴R⁵)_q-.

20 R⁶ is a substituent on carbon and is selected from halo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkanoyl, N-(C₁₋₄alkyl)amino, C₁₋₄alkylS(O)_a wherein a is 0 or 2, carbocyclyl, heterocyclyl and heterocyclylC₀₋₄alkylene-Y-; wherein R⁶ may be optionally substituted on carbon by one or more groups selected from R¹⁸;

Y is -S(O)₂-;

25 R¹⁸ is selected from halo, cyano, hydroxy, carbocyclyl and heterocyclyl.

R⁶ is a substituent on carbon and is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, methyl, *t*-butyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, methylthio, mesyl, phenyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl, and piperidin-1-ylsulphonyl.

30 R⁶ is a substituent on carbon and is selected from fluoro, chloro, cyano, carbamoyl, trifluoromethyl, methyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, mesyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl and piperidin-1-ylsulphonyl.

m is 0-2; wherein the values of R⁶ may be the same or different.

m is 0 or 1.

m is 0.

m is 1.

Therefore in a further aspect of the invention there is provided the use of a compound
5 of formula (I) (as depicted above) wherein:

Ring A is selected from phenyl, naphthyl, thienyl, furyl, thiazolyl, pyridyl, benzothienyl, imidazolyl or pyrazolyl;

R¹ is selected from halo, cyano, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy,

10 *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkylS(O)_a wherein a is 0, carbocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; or two R¹ on adjacent carbons may form an oxyC₁₋₄alkoxy group; wherein R¹ may be optionally substituted on carbon by one or more groups selected from R⁷;

Y is -S(O)_a- or -O-; wherein a is 0 to 2; and

R⁷ is halo;

15 n is 0-3; wherein the values of R¹ may be the same or different;

R², R³, R⁴ and R⁵ are independently selected from hydrogen, hydroxy, amino, cyano, C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclylC₁₋₄alkyl, heterocyclylC₁₋₄alkyl; wherein R², R³, R⁴ and R⁵ may be independently optionally substituted on carbon by one or more groups selected from R⁹;

20 R⁹ is selected from halo, nitro, cyano, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, C₁₋₄alkoxycarbonyl and carbocyclyl; wherein R⁹ may be optionally substituted on carbon by one or more R²⁶; wherein

R²⁶ is hydroxy;

X is -S(O)_a-, -O-, -NR¹³-, -NR¹⁵C(O)-, -SO₂NR¹⁶- or -NR¹⁶SO₂-; wherein a is 0 or 2;

25 R¹³, R¹⁵ and R¹⁶ are independently selected from hydrogen, phenyl and C₁₋₄alkyl;

q is 0 or 1;

p is 0 or 1;

Ring B is phenyl, thienyl, piperidinyl, morpholinyl, naphthyl, 2,6-dioxocyclohexyl, cyclohexyl, pyridyl, imidazolyl, 1,2,4-triazolyl, thiomorpholinyl, coumarinyl, pyrimidinyl,
30 phthalidyl, pyrazinyl, pyridazinyl, benzimidazolyl or [1,2,4]triazolo[4,3-a]pyrimidinyl; wherein if said imidazolyl or morpholinyl is linked via a carbon it may be optionally substituted on the -NH- by a group selected from R¹⁷;

R¹⁷ is selected from C₁₋₄alkyl or benzyl;

R^6 is a substituent on carbon and is selected from halo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, N -(C_{1-4} alkyl)amino, C_{1-4} alkylS(O)_n wherein a is 0 or 2, carbocyclyl, heterocyclyl and heterocyclylC₀₋₄alkylene-Y-; wherein R^6 may be optionally substituted on carbon by one or more groups selected from R^{18} ;

5 Y is -S(O)₂-;

R^{18} is selected from halo, cyano, hydroxy, carbocyclyl and heterocyclyl; and

m is 0-3; wherein the values of R^6 may be the same or different.

or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for use in the inhibition of 11 β HSD1.

10 Therefore in a further aspect of the invention there is provided the use of a compound of formula (I) (as depicted above) wherein:

Ring A is selected from phenyl, naphth-2-yl, thien-2-yl, thien-3-yl, fur-2-yl, thiazol-2-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, benzothien-3-yl, imidazol-2-yl or pyrazol-1-yl;

R^1 is selected from fluoro, chloro, bromo, cyano, hydroxy, methyl, *t*-butyl,

15 trifluoromethyl, methoxy, ethoxy, butoxy, dimethylamino, methylthio, 4-chlorophenyl, benzyloxy, morpholin sulphonyl and tetrahydrofur-2-yloxy; or two R^1 on adjacent carbons may form oxymethyleneoxy;

n is 0-3; wherein the values of R^1 may be the same or different;

R^2 , R^3 , R^4 and R^5 are independently selected from hydrogen, hydroxy, amino, cyano, 20 methyl, ethyl, propyl, isopropyl, ethoxy, isobutoxy, cyanomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminomethyl, *N,N*-dimethylaminomethyl, *N,N*-diethylaminomethyl, *N,N*-dipropylaminomethyl, *N,N*-diisopropylaminomethyl, 2-hydroxyethylaminomethyl, methylamino, ethylamino, propylamino, isopropylamino, 2-hydroxyethylamino, 2-(*N,N*-diethylamino)ethylamino, 3-(*N,N*-dimethylamino)propylamino, 25 *N,N*-dipropylamino, phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, piperidin-1-yl, indol-1-yl, 1,3-benzodioxol-5-yl, benzyl, α -cyanobenzyl, 2-fluorobenzyl, 2-nitrobenzyl, 2-ethoxycarbonylbenzyl, 3-nitrobenzyl, 3-trifluoromethylbenzyl, 3-methoxycarbonylbenzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-nitrobenzyl, 4-methoxycarbonylbenzyl, 2,4-dichlorobenzyl, 30 3-nitro-6-methoxybenzyl, benzylamino, phenethylaminopyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, morpholinomethyl, 5-nitrofur-2-ylmethyl, 2-methylthiazol-4-ylmethyl, 2-chlorothiazol-5-ylmethyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl;

X is -S-, -S(O)₂-, -O-, -NH-, -NMe-, -NHC(O)-, -SO₂NMe- or -NPhSO₂-;

q is 0 or 1;

p is 0 or 1;

Ring B is phenyl, thien-2-yl, thien-3-yl, piperidin-1-yl, morpholino, morpholin-2-yl, 4-benzylmorpholin-2-yl, naphth-1-yl, naphth-2-yl, 2,6-dioxocyclohex-1-yl, cyclohexyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-1-yl, 1-methylimidazol-2-yl, 1,2,4-triazol-1-yl, thiomorpholino, coumarin-7-yl, pyrimidin-2-yl, phthalid-3-yl, pyrazin-2-yl, pyridazin-3-yl, benzimidazol-1-yl or [1,2,4]triazolo[4,3-a]pyrimidin-5-yl;

R⁶ is a substituent on carbon and is selected from fluoro, chloro, bromo, cyano, hydroxy, amino, carbamoyl, trifluoromethyl, methyl, *t*-butyl, cyanomethyl, methoxy, ethoxy, acetyl, 2-hydroxyethylamino, methylthio, mesyl, phenyl, 4-fluorophenyl, 2-thiazolin-2-yl, morpholinomethyl, and piperidin-1-ylsulphonyl;

m is 0-3; wherein the values of R⁶ may be the same or different;
or a pharmaceutically acceptable salt thereof;
in the manufacture of a medicament for use in the inhibition of 11 β HSD1.

15 In another aspect of the present invention, a suitable compound of the invention, or a pharmaceutically acceptable salt thereof, is selected from Group A:

(benzyl)-[4-(morpholinomethyl)phenyl]-ketone;

(2-methylpyrid-5-ylmethyl)-(phenyl)-ketone;

[2-(3-chlorophenyl)-2-(1,2,4-triazol-1-yl)ethyl]-(phenyl)-ketone;

20 (4-chlorobenzyl)-(2-bromophenyl)-ketone;

(4-chlorobenzyl)-(3-bromophenyl)-ketone;

(3,4-dichlorobenzyl)-(3,4-dichlorophenyl)-ketone;

[α -(4-fluorobenzyl)benzyl]-(pyrid-3-yl)-ketone;

{ α -[3-(*N,N*-dimethylamino)propylamino]benzyl}-(pyrid-3-yl)-ketone;

25 (2,4-dibromophenoxymethyl)-(phenyl)-ketone;

[α -(cyclohexylamino)-4-chlorobenzyl]-(4-chlorophenyl)-ketone;

[1-(cyclohexylamino)-1-(1,3-benzodioxol-5-yl)methyl]-(1,3-benzodioxol-5-yl)-ketone;

[α -(cyclohexylamino)-3,4-dimethoxybenzyl]-(2-chlorophenyl)-ketone;

[α -(cyclohexylamino)-4-methylbenzyl]-(4-methylphenyl)-ketone;

30 [α -(cyclohexylamino)-2-chlorobenzyl]-(2-chlorophenyl)-ketone;

[α -hydroxy- α -(*N,N*-dipropylaminomethyl)benzyl]-(phenyl)-ketone;

[α -hydroxy- α -(*N,N*-diisopropylaminomethyl)benzyl]-(phenyl)-ketone;

[α -hydroxy- α -(*N,N*-diethylaminomethyl)-4-methoxybenzyl]-(4-methoxyphenyl)-ketone;

- [α -hydroxy- α -(*N,N*-diethylaminomethyl)-4-methylbenzyl]-(4-methylphenyl)-ketone;
{ α -hydroxy- α -[2-(hydroxyethyl)aminomethyl]benzyl}-(phenyl)-ketone;
[α -hydroxy- α -(propylaminomethyl)benzyl]-(phenyl)-ketone;
[α -hydroxy- α -(isopropylaminomethyl)benzyl]-(phenyl)-ketone;
- 5 (phthalid-3-ylmethyl)-(4-chlorophenyl)-ketone;
[2-(3-trifluoromethylphenyl)-1-(1,2,4-triazol-1-yl)ethyl]-(4-fluorophenyl)-ketone;
[2-(4-nitrophenyl)-1-(1,2,4-triazol-1-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(2-fluorophenyl)-1-(1,2,4-triazol-1-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(2,4-dichlorophenyl)-1-(1,2,4-triazol-1-yl)ethyl]-(phenyl)-ketone;
- 10 (4-bromobenzyl)-(4-fluorophenyl)-ketone;
[2-(4-fluorophenyl)-1-(pyrazin-2-yl)ethyl]-(phenyl)-ketone;
(phthalid-3-ylmethyl)-(4-fluorophenyl)-ketone;
[2-(2-fluorophenyl)-1-(pyrazin-2-yl)ethyl]-(fur-2-yl)-ketone;
[2-(4-chlorophenyl)-1-(pyrid-3-yl)ethyl]-(4-chlorophenyl)-ketone;
- 15 [2-(2,4-dichlorophenyl)-1-(pyridazin-3-yl)ethyl]-(phenyl)-ketone;
[2-(4-chlorophenyl)-1-(pyridazin-3-yl)ethyl]-(phenyl)-ketone;
[2-(4-chlorophenyl)-1-(pyrazin-2-yl)ethyl]-(pyrid-3-yl)-ketone;
[2-(4-chlorophenyl)-1-(pyrazin-2-yl)ethyl]-(fur-2-yl)-ketone;
(3,4-dichlorobenzyl)-(4-chlorophenyl)-ketone;
- 20 (2-fluorobenzyl)-(4-chlorophenyl)-ketone;
[2-(4-fluorophenyl)-1-(pyrazin-2-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(1,2,4-triazol-1-yl)-3-methylbutyl]-(phenyl)-ketone;
[2-(4-chlorophenyl)-1-(phenyl)ethyl]-(pyrid-3-yl)-ketone;
[2-(2-fluorophenyl)-1-(1,2,4-triazol-1-yl)ethyl]-(thien-2-yl)-ketone;
- 25 [2-(phenyl)-1-(imidazol-1-yl)ethyl]-(4-chlorophenyl)-ketone;
[1-methyl-1-(1,2,4-triazol-1-yl)ethyl]-(4-chlorophenyl)-ketone;
[2-(2-aminophenylthio)-2-(4-methoxyphenyl)ethyl]-(4-methoxyphenyl)-ketone;
[2-(2,4-dichlorophenyl)-1-(1,2,4-triazol-1-yl)ethyl]-(2-chlorothien-5-yl)-ketone;
[1-(hydroxy)-1-(thien-3-yl)methyl]-(thien-3-yl)-ketone;
- 30 (α -hydroxybenzyl)-(4-*t*-butylphenyl)-ketone;
[2-(4-chlorophenyl)-1-(4-methylphenyl)ethyl]-(pyrid-3-yl)-ketone;
[(7-methyl[1,2,4]triazolo[4,3-*a*]pyrimidin-5-yl)oxymethyl]-(4-chlorophenyl)-ketone;
(4-phenyl-2,6-dioxocyclohexylmethyl)-(4-bromophenyl)-ketone;

- (α -ethoxy- α -ethylaminomethylbenzyl)-(phenyl)-ketone;
 [α -(2-oxocyclopentyl)benzyl]-(phenyl)-ketone;
 [α -(5-chloropyrimidin-2-yl)benzyl]-(phenyl)-ketone;
 (phenoxymethyl)-(3,5-dimethyl-2,3-dihydro-pyrazol-2-yl)-ketone;
 5 [2-(piperidin-1-yl)-1-(4-methylphenylsulphonyl)]-(phenyl)-ketone;
 (benzimidazol-1-ylmethyl)-(4-bromophenyl)-ketone;
 {[2-(2-hydroxyethylamino)-benzimidazol-1-yl]methyl}-(thien-2-yl)-ketone;
 (2-carbamoylphenoxymethyl)-(4-bromophenyl)-ketone;
 (morpholin-2-ylmethyl)-(phenyl)-ketone;
 10 (pyrimidin-2-ylsulphanylmethyl)-(4-bromophenyl)-ketone;
 (4-acetylbenzyl)-(4-chlorophenyl)-ketone;
 [(1-methylimidazol-2-yl)sulphanylmethyl]-(4-chlorophenyl)-ketone;
 (benzimidazol-1-ylmethyl)-(2,4-dichlorophenyl)-ketone;
 (4-methylbenzyl)-[4-(tetrahydropyran-2-yloxy)phenyl]-ketone;
 15 (phenylsulphonylmethyl)-(pyrid-2-yl)-ketone;
 (4-chlorophenoxymethyl)-(3,5-difluorophenyl)-ketone;
 [(1-(naphth-2-yl)-1-(hydroxy)methyl]-(4-dimethylaminophenyl)-ketone;
 (α -hydroxy-4-methoxybenzyl)-(naphth-2-yl)-ketone;
 (4-chlorophenethyl)-(2,4-difluorophenyl)-ketone;
 20 (4-fluorophenoxymethyl)-(4-chlorophenyl)-ketone;
 (phenoxymethyl)-(4-trifluoromethyl-2-fluorophenyl)-ketone;
 [1-methyl-1-(1,2,4-triazol-1-yl)ethyl]-(4-trifluoromethyl-2-fluorophenyl)-ketone;
 (4-fluorophenethyl)-(4-trifluoromethylphenyl)-ketone;
 (4-fluorophenethyl)-(2,4-difluorophenyl)-ketone;
 25 (4-fluorophenethyl)-(4-chlorophenyl)-ketone;
 (benzyl)-(3,4-dichlorophenyl)-ketone;
 [4-(piperdin-1-ylsulphonyl)phenoxymethyl]-(phenyl)-ketone;
 [2-(morpholinomethyl)-3,5-dimethylphenoxymethyl]-(phenyl)-ketone;
 (phenylsulphonylmethyl)-(3,4-dihydroxyphenyl)-ketone; and
 30 (4-methylphenylsulphonylmethyl)-(4-chloro-3-methylphenyl)-ketone.

In a further aspect of the invention, there is provided the use of a compound or a pharmaceutically acceptable salt thereof, selected from Group B:

(2,2-diphenylethyl)-(phenyl)-ketone;

- (1,2-diphenylethyl)-(4-chlorophenyl)-ketone;
(1-phenylpropyl)-(phenyl)-ketone;
[2-(piperidin-1-yl)-1-(phenyl)ethyl]-(phenyl)-ketone;
[2-(morpholino)-1-(phenyl)ethyl]-(phenyl)-ketone;
5 [2-(dimethylamino)-1-(phenyl)ethyl]-(phenyl)-ketone;
[2-(phenyl)-1-(imidazol-1-yl)ethyl]-(phenyl)-ketone;
(1,2-diphenylethyl)-(phenyl)-ketone;
(α -propylbenzyl)-(phenyl)-ketone;
[α -(cyanomethyl)benzyl]-(phenyl)-ketone;
10 [*N*-(4-methylphenylsulphonyl)anilinomethyl]-(phenyl)-ketone;
(phenylsulphonylmethyl)-(phenyl)-ketone;
[(1-methylimidazol-2-yl)sulphanylmethyl]-(4-bromophenyl)-ketone;
(4-methylphenylsulphonylmethyl)-(4-bromophenyl)-ketone;
(4-chlorophenylsulphonylmethyl)-(phenyl)-ketone;
15 (4-chlorophenylsulphonylmethyl)-(phenyl)-ketone;
(phenylsulphonylmethyl)-(4-methoxyphenyl)-ketone;
(phenylsulphonylmethyl)-(4-methylphenyl)-ketone;
(4-methylphenylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(4-chlorophenylsulphonylmethyl)-(4-bromophenyl)-ketone;
20 (benzylsulphonylmethyl)-(phenyl)-ketone;
(2-carbamoylphenoxymethyl)-(phenyl)-ketone;
(naphth-2-yloxymethyl)-(phenyl)-ketone;
(phenoxymethyl)-(phenyl)-ketone;
(4-chlorophenoxymethyl)-(phenyl)-ketone;
25 (phenoxymethyl)-(4-chlorophenyl)-ketone;
(4-cyanophenoxymethyl)-(phenyl)-ketone;
(4-*t*-butylphenoxymethyl)-(4-chlorophenyl)-ketone;
(*N*-methylanilinomethyl)-(phenyl)-ketone;
(4-chlorobenzamidomethyl)-(4-bromophenyl)-ketone;
30 [1-(cyano)-1-(thien-2-yl)ethyl]-(phenyl)-ketone;
(phenethyl)-(4-bromophenyl)-ketone;
[2-(2-methoxyphenyl)ethyl]-(phenyl)-ketone;
(2-(cyano)-2-(phenyl)ethyl]-(phenyl)-ketone;

- (phenethyl)-(phenyl)-ketone;
(phenethyl)-(2-methoxyphenyl)-ketone;
(3,4-dimethoxyphenethyl)-(phenyl)-ketone;
(phenethyl)-(4-chlorophenyl)-ketone;
- 5 (α-hydroxybenzyl)-(phenyl)-ketone;
(α-hydroxy-4-chlorobenzyl)-(4-chlorophenyl)-ketone;
[α-hydroxy-α-(*N,N*-diethylaminomethyl)benzyl]-(phenyl)-ketone;
[α-hydroxy-α-(piperidin-1-ylmethyl)benzyl]-(phenyl)-ketone;
[α-hydroxy-α-(*N,N*-dimethylaminomethyl)benzyl]-(phenyl)-ketone;
- 10 [α-hydroxy-α-(morpholinomethyl)benzyl]-(phenyl)-ketone;
(α-hydroxy-4-chlorobenzyl)-(4-methoxyphenyl)-ketone;
(α-ethoxybenzyl)-(phenyl)-ketone;
(α-hydroxy-α-ethylbenzyl)-(phenyl)-ketone;
(α-hydroxybenzyl)-(4-methoxyphenyl)-ketone;
- 15 [1-(1,2,4-triazol-1-yl)-1-(ethoxy)methyl]-(4-chlorophenyl)-ketone;
[1-(thien-2-yl)-1-(hydroxy)methyl]-(thien-2-yl)-ketone;
(α-hydroxybenzyl)-(4-methoxyphenyl)-ketone;
(α-hydroxy-4-methoxybenzyl)-(phenyl)-ketone;
(α-isopropoxybenzyl)-(phenyl)-ketone;
- 20 (α-isobutoxybenzyl)-(phenyl)-ketone;
(α-aminobenzyl)-(4-chlorophenyl)-ketone;
(α-[2-(*N,N*-diethylamino)ethylamino]benzyl)-(phenyl)-ketone;
(α-isopropylaminobenzyl)-(phenyl)-ketone;
[α-(piperidin-1-yl)-4-chlorobenzyl]-(4-chlorophenyl)-ketone;
- 25 [α-(benzylamino)benzyl]-(phenyl)-ketone;
[α-(4-chloroanilino)benzyl]-(phenyl)-ketone;
[α-(cyclohexylamino)benzyl]-(phenyl)-ketone;
[α-(*N,N*-dipropylamino)benzyl]-(phenyl)-ketone;
[α-(2-hydroxyethylamino)benzyl]-(phenyl)-ketone;
- 30 [α-(phenethylamino)benzyl]-(phenyl)-ketone;
[α-(ethylamino)benzyl]-(phenyl)-ketone;
[α-(propylamino)benzyl]-(phenyl)-ketone;

- [α -(methylamino)benzyl]-(phenyl)-ketone;
[α -(anilino)benzyl]-(fur-2-yl)-ketone;
[1-(benzimidazol-1-yl)-1-(anilino)methyl-(phenyl)-ketone;
(4-chlorobenzyl)-(phenyl)-ketone;
5 (benzyl)-(4-ethoxyphenyl)-ketone;
(4-methoxybenzyl)-(4-methoxyphenyl)-ketone;
(benzyl)-(4-methylphenyl)-ketone;
[4-(benzyl)morpholin-2-ylmethyl]-(phenyl)-ketone;
(pyrid-2-ylmethyl)-(4-chlorophenyl)-ketone;
10 (2-chlorobenzyl)-(4-chlorophenyl)-ketone;
(4-chlorobenzyl)-(4-chlorophenyl)-ketone;
(pyrid-3-ylmethyl)-(4-chlorophenyl)-ketone;
(4-bromobenzyl)-(4-chlorophenyl)-ketone;
(2,4-dichlorobenzyl)-(4-chlorophenyl)-ketone;
15 (4-chlorobenzyl)-(4-methylphenyl)-ketone;
(4-chlorobenzyl)-(4-bromophenyl)-ketone;
(benzyl)-(2-chlorophenyl)-ketone;
(4-methoxybenzyl)-(phenyl)-ketone;
(α -methylbenzyl)-(phenyl)-ketone;
20 (benzyl)-[4-(4-chlorophenyl)phenyl]-ketone;
(4-fluorobenzyl)-(4-bromophenyl)-ketone;
(4-chlorobenzyl)-(4-methoxyphenyl)-ketone;
(4-methylbenzyl)-(4-methoxyphenyl)-ketone;
(pyrid-2-ylmethyl)-(phenyl)-ketone;
25 (α,α -dimethylbenzyl)-(phenyl)-ketone;
(4-methylbenzyl)-(pyrid-3-yl)-ketone;
(pyrid-4-ylmethyl)-(pyrid-4-yl)-ketone;
(4-methoxybenzyl)-(4-bromophenyl)-ketone;
(4-methylthiobenzyl)-(4-fluorophenyl)-ketone;
30 (benzyl)-(4-benzyloxyphenyl)-ketone;
(4-fluorobenzyl)-(4-fluorophenyl)-ketone;
(α -methylbenzyl)-(phenyl)-ketone;
(4-methoxybenzyl)-(4-fluorophenyl)-ketone;

- (thiomorpholinomethyl)-(thianaphthen-3-yl)-(phenyl)-ketone;
(benzyl)-(4-butoxyphenyl)-ketone;
(2,2-diphenylethyl)-(2,4,6-trimethylphenyl)-ketone;
[2-(2-hydroxyphenyl)-2-phenylethyl]-(phenyl)-ketone;
- 5 (cyclohexylmethyl)-(phenyl)-ketone;
(benzyl)-(2-bromothien-5-yl)-ketone;
(1,2-diphenyl-2-cyanoethyl)-(phenyl)-ketone;
(4-methoxybenzyl)-(3-bromophenyl)-ketone;
(α -hydroxybenzyl)-(3-methoxyphenyl)-ketone;
- 10 [α -(pyrrolidin-1-ylmethyl)benzyl]-(phenyl)-ketone;
[α -(pyridin-2-ylamino)-4-methoxybenzyl]-(4-methoxyphenyl)-ketone;
(4-chlorobenzyl)-(4-fluorophenyl)-ketone;
(benzyl)-[4-(tetrahydropyran-2-yloxy)phenyl]-ketone;
(4-chlorophenylsulphonylmethyl)-(4-chlorophenyl)-ketone;
- 15 (4-methyl- α -hydroxybenzyl)-(4-chlorophenyl)-ketone;
(4-methylbenzyl)-(4-chlorophenyl)-ketone;
(4-fluoro- α -hydroxybenzyl)-(4-fluorophenyl)-ketone;
(4-methoxy- α -hydroxybenzyl)-(4-methoxyphenyl)-ketone;
(α -methyl- α -hydroxybenzyl)-(phenyl)-ketone;
- 20 (1-methyl-1-morpholinoethyl)-(4-methylsulphanylphenyl)-ketone;
[2-(phenylsulphonyl)-2-(phenyl)ethyl]-(phenyl)-ketone
(1-methyl-1-pyrid-3-ylethyl)-(pyrid-3-yl)-ketone;
(1,3-diphenylprop-2-yl)-(phenyl)-ketone;
(naphth-1-yloxymethyl)-(phenyl)-ketone;
- 25 (phenoxymethyl)-(4-methylphenyl)-ketone;
(4-methylcoumarin-7-yloxymethyl)-(4-methoxyphenyl)-ketone;
(imidazol-1-ylmethyl)-(2-chlorothien-5-yl)-ketone;
(thien-2-ylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(1-methylimidazol-2-ylsulphanyl-methyl)-(3,4-difluorophenyl)-ketone;
- 30 (1-methylimidazol-2-ylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(3-trifluoromethylpyrid-6-ylsulphonylmethyl)-(4-chlorophenyl)-ketone;
(4-methyl- α -hydroxybenzyl)-(4-methylphenyl)-ketone;
(4-bromophenoxymethyl)-(phenyl)-ketone;

(4-ethoxyanilinomethyl)-(4-methylphenyl)-ketone;

(2,4,6-trichlorophenoxyethyl)-(phenyl)-ketone;


in the manufacture of a medicament for use in the inhibition of 11 β HSD1.

In another aspect of the invention, preferred compounds of the invention are any one
5 of the Examples or a pharmaceutically acceptable salt thereof.

In another aspect of the invention, preferred compounds of the invention are any one
of the Reference Examples or a pharmaceutically acceptable salt thereof.


Another aspect of the present invention provides a process for preparing a compound
of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable
10 groups are, unless otherwise specified, as defined in formula (I)) comprises of:

Process 1): reacting a compound of formula (II):



(II)


wherein V is a displaceable group; with an organometallic reagent of formula (III):



(III)

wherein M is a metal reagent;

Process 2): for compounds of formula (I) wherein one of R² and R³ is hydroxy; reacting a
compound of formula (IV):




(IV)

with a compound of formula (V) or (VI):




25 wherein M is a metal reagent;

Process 3): for compounds of formula (I) wherein one of R^4 and R^5 is hydroxy; reacting a compound of formula (VII):




5 with a compound of formula (VIII) or (IX):



wherein M is a metal reagent;

Process 4): for compounds of formula (I) wherein p is 0, q is 1 and R^3 and R^5 are hydrogen;


10 hydrogenating compound of formula (X):




(or its corresponding Z isomer);

Process 5) for compounds of formula (I) wherein p is 1, X is $-SO_2-$ and q is 0; reacting a


15 compound of formula (XI):



with a compound of formula (XII):




Process 6) for compounds of formula (I) wherein Ring A is a nitrogen linked heteroaryl;
 reacting a compound of formula (II), wherein L is hydroxy, or an activated derivative thereof
 forming an activated acid, with a compound of formula (XIII):



5


(XIII)

Process 7) for compounds of formula (I) wherein X is $-C(O)NR^{14}$ -; reacting an acid of
 formula (XIV):




(XIV)

10 or an activated derivative thereof; with an amine of formula (XV):



(XV)


Process 8) for compounds of formula (I) wherein X is $-NR^{15}C(O)-$; reacting an amine of
 formula (XVI):



15

(XVI)


with an acid of formula (XVII):




(XVII)

20 or an activated derivative thereof;


Process 9) for compounds of formula (I) wherein X is $-\text{SO}_2\text{NR}^{16}-$; reacting a compound of formula (XVIII):



5 wherein L is a displaceable group; with an amine of formula (XIX):




Process 10) for compounds of formula (I) wherein X is $-\text{NR}^{16}\text{SO}_2-$; reacting an amine of formula (XX):




10

with a compound of formula (XXI):




15 wherein L is a displaceable group;

Process 11) for compounds of formula (I) wherein X is $-\text{O}-$, $-\text{NR}^{13}-$ or $-\text{S}-$; reacting a compound of formula (XX):




wherein V is -OH, -NR¹³H or -SH; with a compound of formula (XXI):




wherein L is a displaceable group;

- 5 *Process 12)* for compounds of formula (I) wherein X is -O-, -NR¹³- or -S-; reacting a compound of formula (XX):



wherein L is a displaceable group; with a compound of formula (XXI):



wherein V is -OH, -NR¹³H or -SH;

and thereafter if necessary or desirable:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- 15 ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt thereof.

L is a displaceable group, suitable values for L include halo, particularly chloro or bromo, or mesyloxy.

- V is a displaceable group, suitable values for V include the Weinreb amide *N*-methyl-
20 *N*-methoxyamine.

M is a metal reagent. Suitable values for M include Grignard reagents such as MgBr and lithium.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters.

The reactions described above may be performed under standard conditions. The intermediates described above are commercially available, are known in the art or may be prepared by known procedures.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali

metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an

arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possess 11 β HSD1 inhibitory activity. These properties may be assessed using the following assay.

Assay

HeLa cells (human cervical carcinoma derived cells) were stably transfected with a construct containing four copies of the glucocorticoid response element (GRE) linked to a beta-galactosidase reporter gene (3 kb lac Z gene derived from pSV-B-galactosidase). These cells were then further stably transfected with a construct containing full-length human 11 β HSD1 enzyme (in pCMVHyg) to create GRE4- β Gal/11 β HSD1 cells. The principal of the assay is as follows. Cortisone is freely taken up by the cells and is converted to cortisol by

11 β HSD1 oxo-reductase activity and cortisol (but not cortisone) binds to and activates the glucocorticoid receptor. Activated glucocorticoid receptor then binds to the GRE and initiates transcription and translation of β -galactosidase. Enzyme activity can then be assayed with high sensitivity by colourimetric assay. Inhibitors of 11 β HSD1 will reduce the conversion of
5 cortisone to cortisol and hence decrease the production of β -galactosidase.

Cells were routinely cultured in DMEM (Invitrogen, Paisley, Renfrewshire, UK) containing 10% foetal calf serum (LabTech), 1% glutamine (Invitrogen), 1% penicillin & streptomycin (Invitrogen), 0.5 mg/ml G418 (Invitrogen) & 0.5mg/ml hygromycin (Boehringer). Assay media was phenol red free-DMEM containing 1% glutamine, 1%
10 penicillin & streptomycin.

Compounds (1mM) to be tested were dissolved in dimethyl sulphoxide (DMSO) and serially diluted into assay media containing 10% DMSO. Diluted compounds were then plated into transparent flat-bottomed 384 well plates (Matrix, Hudson NH, USA).

The assay was carried out in 384 well microtitre plate (Matrix) in a total volume of
15 50 μ l assay media consisting of cortisone (Sigma, Poole, Dorset, UK, 1 μ M), HeLa GRE4- β Gal/11 β HSD1 cells (10,000 cells) plus test compounds (3000 to 0.01 nM). The plates were then incubated in 5% O₂, 95% CO₂ at 37°C overnight.

The following day plates were assayed by measurement of β -galactosidase production.

A cocktail (25 μ l) consisting of 10X Z-buffer (600 mM Na₂HPO₄, 400 mM
20 NaH₂PO₄.2H₂O, 100 mM KCl, 10 mM MgSO₄.7H₂O, 500 mM β -mercaptoethanol, pH 7.0), SDS (0.2%), chlorophenol red- β -D-galactopyranoside (5mM, Roche Diagnostics) was added per well and plates incubated at 37°C for 3-4hours. β -Galactosidase activity was indicated by a yellow to red colour change (absorbance at 570nm) measured using a Tecan Spectrafluor Ultra.

25 The calculation of median inhibitory concentration (IC₅₀) values for the inhibitors was performed using Origin 6.0 (Microcal Software, Northampton MA USA). Dose response curves for each inhibitor were plotted as OD units at each inhibitor concentration with relation to a maximum signal (cortisone, no compound) and IC₅₀ values calculated. Compounds of the present invention typically show an IC₅₀ <10 μ M.

30 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in

association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical
5 administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (I), or a pharmaceutically acceptable salt thereof, will normally be administered to a warm-blooded animal at a unit dose within the range 0.1 –
10 50 mg/kg that normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-1000 mg of active ingredient. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

15 We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective 11β HSD1 inhibitors, and accordingly have value in the treatment of disease states associated with metabolic syndrome.

It is to be understood that where the term "metabolic syndrome" is used herein, this relates to metabolic syndrome as defined in 1) and/or 2) or any other recognised definition of
20 this syndrome. Synonyms for "metabolic syndrome" used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term "metabolic syndrome" is used herein it also refers to Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X.

According to a further aspect of the present invention there is provided a compound of
25 the formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

Thus according to this aspect of the invention there is provided a compound of the
30 formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament.

According to another feature of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 11β HSD1 inhibitory effect in a warm-blooded animal, such as man.

5 According to another feature of the invention there is provided the use of a compound of the formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A or the Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 11β HSD1 inhibitory effect in a warm-blooded animal, such as man.

10 According to another feature of the invention there is provided the use of a compound selected from Group B or the Reference Examples, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an 11β HSD1 inhibitory effect in a warm-blooded animal, such as man.

Where production of or producing an 11β HSD1 inhibitory effect is referred to suitably
15 this refers to the treatment of metabolic syndrome. Alternatively, where production of an 11β HSD1 inhibitory effect is referred to this refers to the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, particularly diabetes and obesity. Alternatively, where production of an 11β HSD1 inhibitory effect is referred to this refers to the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders
20 or depression.

According to a further feature of this aspect of the invention there is provided a method for producing an 11β HSD1 inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

25 According to a further feature of this aspect of the invention there is provided a method for producing an 11β HSD1 inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig) or a pharmaceutically acceptable salt thereof, or a compound selected from Group A or the Examples, or a
30 pharmaceutically acceptable salt thereof.

According to a further feature of this aspect of the invention there is provided a method for producing an 11β HSD1 inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount

of a compound selected from Group B or the Reference Examples, or a pharmaceutically acceptable salt thereof.

In addition to their use in therapeutic medicine, the compounds of formula (I), or a pharmaceutically acceptable salt thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of 11 β HSD1 in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

The inhibition of 11 β HSD1 described herein may be applied as a sole therapy or may involve, in addition to the subject of the present invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Simultaneous treatment may be in a single tablet or in separate tablets. For example agents than might be co-administered with 11 β HSD1 inhibitors, particularly those of the present invention, may include the following main categories of treatment:

- 1) Insulin and insulin analogues;
- 2) Insulin secretagogues including sulphonylureas (for example glibenclamide, glipizide) and prandial glucose regulators (for example repaglinide, nateglinide);
- 3) Insulin sensitising agents including PPAR γ agonists (for example pioglitazone and rosiglitazone);
- 4) Agents that suppress hepatic glucose output (for example metformin);
- 5) Agents designed to reduce the absorption of glucose from the intestine (for example acarbose);
- 6) Agents designed to treat the complications of prolonged hyperglycaemia; e.g. aldose reductase inhibitors
- 7) Other anti-diabetic agents including phosphotyrosine phosphatase inhibitors, glucose 6 - phosphatase inhibitors, glucagon receptor antagonists, glucokinase activators, glycogen phosphorylase inhibitors, fructose 1,6 bisphosphatase inhibitors, glutamine:fructose -6-phosphate amidotransferase inhibitors
- 8) Anti-obesity agents (for example sibutramine and orlistat);
- 9) Anti- dyslipidaemia agents such as, HMG-CoA reductase inhibitors (statins, eg pravastatin); PPAR α agonists (fibrates, eg gemfibrozil); bile acid sequestrants (cholestyramine); cholesterol absorption inhibitors (plant stanols, synthetic inhibitors);

ileal bile acid absorption inhibitors (IBATi), cholesterol ester transfer protein inhibitors and nicotinic acid and analogues (niacin and slow release formulations);

10) Antihypertensive agents such as, β blockers (eg atenolol, inderal); ACE inhibitors (eg lisinopril); calcium antagonists (eg. nifedipine); angiotensin receptor antagonists (eg candesartan), α antagonists and diuretic agents (eg. furosemide, benzthiazide);

11) Haemostasis modulators such as, antithrombotics, activators of fibrinolysis and antiplatelet agents; thrombin antagonists; factor Xa inhibitors; factor VIIa inhibitors; antiplatelet agents (eg. aspirin, clopidogrel); anticoagulants (heparin and Low molecular weight analogues, hirudin) and warfarin; and

12) Anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (eg. aspirin) and steroidal anti-inflammatory agents (eg. cortisone).

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

15 Examples

The invention will now be illustrated in the following non limiting Examples, in which standard techniques known to the skilled chemist and techniques analogous to those described in these Examples may be used where appropriate, and in which, unless otherwise stated:

(i) evaporations were carried out by rotary evaporation in vacuo and work up procedures were

carried out after removal of residual solids such as drying agents by filtration;

(ii) all reactions were carried out under an inert atmosphere at ambient temperature, typically in the range 18-25°C, with solvents of HPLC grade under anhydrous conditions, unless otherwise stated;

(iii) column chromatography (by the flash procedure) was performed on Silica gel 40-63 μ m

(Merck);

(iv) yields are given for illustration only and are not necessarily the maximum attainable;

(v) the structures of the end products of the formula (I) were generally confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; magnetic resonance chemical shift values were measured in deuterated CDCl_3 (unless otherwise stated)

on the delta scale (ppm downfield from tetramethylsilane); proton data is quoted unless otherwise stated; spectra were recorded on a Varian Mercury-300 MHz, Varian Unity plus-400 MHz, Varian Unity plus-600 MHz or on Varian Inova-500 MHz spectrometer unless otherwise stated data was recorded at 400MHz; and peak multiplicities are shown as follows:

s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; ABq, AB quartet; ABd, AB doublet, ABdd, AB doublet of doublets; dABq, doublet of AB quartets; LCMS were recorded on a Waters ZMD, LC column xTerra MS C₈(Waters), detection with a HP 1100 MS-detector diode array equipped; mass spectra (MS) (loop) were recorded on VG Platform II (Fisons Instruments) with a HP-1100 MS-detector diode array equipped; unless otherwise stated the mass ion quoted is (MH⁺); unless further details are specified in the text, analytical high performance liquid chromatography (HPLC) was performed on Prep LC 2000 (Waters), Cromasil C₈, 7 μm, (Akzo Nobel); MeCN and de-ionised water 10 mM ammonium acetate as mobile phases, with suitable composition;

(vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), HPLC, infra-red (IR), MS or NMR analysis;

(viii) where solutions were dried sodium sulphate was the drying agent;

(ix) where an "ISOLUTE" column is referred to, this means a column containing 2 g of silica, the silica being contained in a 6 ml disposable syringe and supported by a porous disc of 54Å pore size, obtained from International Sorbent Technology under the name "ISOLUTE"; "ISOLUTE" is a registered trade mark;

(x) the following abbreviations may be used hereinbefore or hereinafter:-

DCM	dichloromethane;
EtOAc	ethyl acetate;
MeCN	acetonitrile; and
THF	tetrahydrofuran.

Example 1

25 (Thien-3-ylmethyl)-(4-chlorophenyl)-ketone

A solution of 4-chlorophenyl magnesium bromide in diethyl ether (6.0ml of a 1.0 mol solution, 6.0 mmol) was added to a stirred solution of *N*-methoxy-*N*-methyl-3-thienylmethanamide (Method 1; 370 mg, 2.0 mmol) in tetrahydrofuran (20 ml) at 0°C. The resultant mixture was stirred at ambient temperature overnight, and then quenched with ethanol (50 ml). The resultant mixture was evaporated to dryness and the residue partitioned between water (50 ml) and diethyl ether (100 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography

using 5% EtOAc in hexane as eluent to give the title compound, as a solid (170 mg, 0.72 mmol); NMR: 4.3 (s, 2H), 7.0 (d, 1H), 7.1 (d, 1H), 7.3 (dd, 1H), 7.4 (d, 2H), 7.9 (d, 2H).

Examples 2-3

- 5 The procedure described in Example 1 was repeated using the appropriate Grignard reagent to replace the 4-chlorophenyl magnesium bromide to obtain the compounds described below.

Ex	Compound	NMR
2	(Thien-3-ylmethyl)-(4-fluorophenyl)-ketone	4.3 (s, 2H), 7.0 (d, 1H), 7.1 (m, 3H), 7.3 (dd, 1H), 8.0 (m, 2H)
3	(Thien-3-ylmethyl)-(4-methylphenyl)-ketone	2.4 (s, 3H), 4.3 (s, 2H), 7.0 (d, 1H), 7.1 (d, 1H), 7.3 (m, 3H), 7.9 (dd, 2H)

Example 4

- 10 (α -Methylamino-4-methylbenzyl)-(4-methylphenyl)-ketone

To 4,4'-dimethylbenzoin (500mg, 2.1 mmol) in 40% aq methylamine (1.1ml) was added methylamine hydrochloride (20mg). The reaction was warmed to reflux and stirred at this temperature for 2 hours before addition of further 40% aq methylamine (0.5ml). The reaction was stirred at reflux for a further 3 hours then cooled to room temperature. sat

- 15 NaHCO_3 (15ml) was added and the crude mixture was extracted with ether (2x30ml). The ether layers were combined and washed with brine then dried (MgSO_4), filtered and evaporated under reduced pressure to yield an oil. This crude product was dissolved in ether and then acidified with HCl in ether (~0.2M), the resulting precipitate was filtered off and recrystallised from EtOH to give the product as a white solid (154mg, 25%). NMR
- 20 (DMSO- d_6): 2.25 (s, 3H), 2.35 (s, 3H), 2.45 (s, 3H), 6.35 (s, 1H), 7.25 (d, 2H), 7.30 (d, 2H), 7.45 (d, 2H), 7.90 (d, 2H), 9.90 (br s, 2H); m/z 254.

Examples 5-8

- The procedure described in Example 4 was repeated using the appropriate starting materials to obtain the compounds described below.
- 25

Ex	Compound	M/z	NMR (DMSO-d ₆)
5	(α -Methylamino-4-chlorobenzyl)-(4-chlorophenyl)-ketone	294	2.45 (s, 3H), 6.50 (s, 1H), 7.50 (d, 2H), 7.60 (d, 4H), 8.05 (d, 2H), 9.80 (br s, 1H), 10.2 (br s, 1H)
6	(α -Ethylamino-4-chlorobenzyl)-(4-chlorophenyl)-ketone	308	1.30 (t, 3H), 2.80 (br s, 1H), 2.95 (br s, 1H), 6.50 (br s, 1H), 7.55 (d, 2H), 7.60 (m, 4H), 8.10 (d, 2H), 9.65 (br s, 1H), 9.90 (br s, 1H)
7	(α -Isopropylamino-4-chlorobenzyl)-(4-chlorophenyl)-ketone	322	1.30 (m, 6H), 3.05 (br s, 1H), 6.40 (br s, 1H), 7.50 (d, 2H), 7.60 (d, 2H), 7.70 (d, 2H), 8.15 (d, 2H), 9.50 (br s, 1H)
8	(α -Ethylamino-4-methylbenzyl)-(4-methylphenyl)-ketone	268	1.25 (t, 3H), 2.25 (s, 3H), 2.30 (s, 3H), 2.70 (br s, 1H), 2.90 (br s, 1H), 6.35 (s, 1H), 7.20 (d, 2H), 7.30 (d, 2H), 7.45 (d, 2H), 7.95 (d, 2H), 9.50 (br s, 1H), 9.95 (br s, 1H)

Example 9

(α -Methyl- α -hydroxy-4-fluorobenzyl)-(4-fluorophenyl)-ketone

5 A solution of methyl magnesium chloride in tetrahydrofuran (0.67ml of a 3.0 mol solution, 2.0 mmol) was added to a stirred solution of 4,4'-difluorobenzil (492 mg, 2.0 mmol) in diethyl ether (20 ml) during 30 minutes at ambient temperature. The resultant mixture was stirred at ambient temperature for 30 minutes and then quenched with a saturated aqueous solution of ammonium chloride (2.0 ml) and water (3.0 ml). The ether layer was separated,
 10 washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 20% EtOAc in hexane as eluent to give the title compound as a solid (300 mg, 1.15 mmol); NMR: 1.9 (s, 3H), 4.5 (s, 1H), 7.0 (m, 4H), 7.4 (dd, 2H), 7.75 (dd, 2H).

Examples 10-11

15 The procedure described in Example 9 was repeated using the appropriate Grignard reagent to replace the methyl magnesium chloride and the appropriate benzil to replace the 4,4'-difluorobenzil to obtain the compounds described below.

Ex	Compound	NMR
10	(α -Benzyl- α -hydroxy-4-fluorobenzyl)-(4-fluorophenyl)-ketone	3.3 (d, 1H), 3.7 (d, 1H), 3.7 (s, 1H), 6.95 (m, 4H), 7.05 (m, 2H), 7.2 (m, 3H), 7.45 (dd, 2H), 7.8 (dd, 2H)
11	(α -Ethyl- α -hydroxy-4-fluorobenzyl)-(4-fluorophenyl)-ketone	0.9 (t, 3H), 2.4 (q, 2H), 4.5 (s, 1H), 7.0 (m, 4H), 7.4 (dd, 2H), 7.7 (dd, 2H)

Example 12(α -Ethoxy-4-fluorobenzyl)-(4-fluorophenyl)-ketone

- 5 A solution of ethyl magnesium bromide in tetrahydrofuran (6.0ml of a 1.0 mol solution, 6.0 mmol) was added to a stirred solution of 4,4'-difluorobenzil (492 mg, 2.0 mmol) in diethyl ether (20 ml) during 30 minutes at ambient temperature. The resultant mixture was stirred at ambient temperature for 30 minutes and then quenched with a saturated aqueous solution of ammonium chloride (6.0 ml) and water (6.0 ml). The ether layer was separated,
- 10 washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 10% EtOAc in hexane as eluent to give, as a solid, 1,2 bis-(4-Fluorophenyl)-2-ethoxy-1-ethanone (58 mg, 0.21 mmol). NMR: 1.2 (t, 3H), 3.6 (q, 4H), 5.4 (s, 1H), 7.0 (m, 4H), 7.4 (dd, 2H), 8.0 (dd, 2H).

15 Example 13(2-Thien-2-ylethyl)-(4-chlorophenyl)-ketone

- A solution of 4-chlorophenyl magnesium bromide in diethyl ether (6.0ml of a 1.0 mol solution, 6.0 mmol) was added to a stirred solution of *N*-methoxy-*N*-methyl-2-thienylethanamide (Method 2; 398 mg, 2.0 mmol) in tetrahydrofuran (20 ml) at 0°C. The
- 20 resultant mixture was stirred at ambient temperature overnight, and then quenched with ethanol (50 ml). The resultant mixture was evaporated to dryness and the residue partitioned between water (50 ml) and diethyl ether (100 ml). The ether layer was separated, washed with brine, dried and evaporated to dryness. The residue was purified by column chromatography using 5% EtOAc in hexane as eluent to give the title compound as a solid (250 mg, 1.0
- 25 mmol). NMR: 3.3 (m, 4H), 6.8 (dd, 1H), 6.9 (dd, 1H), 7.1 (dd, 1H), 7.4 (d, 2H), 7.9 (d, 2H).

Reference Examples 1-3 and Examples 14-16

The procedure described in Example 13 was repeated using the appropriate *N*-methoxy-*N*-methyl amide to replace the *N*-methoxy-*N*-methyl-2-thienylethanamide and the appropriate Grignard or lithium reagent to replace the 4-chlorophenyl magnesium bromide to obtain the compounds described below.

Ex	Compound	NMR
RE1	(4-Fluorophenethyl)-(4-fluorophenyl)-ketone	3.0 (t, 2H), 3.2 (t, 2H), 6.9 (dd, 2H), 7.1 (dd, 2H), 7.2 (dd, 2H), 8.0 (dd, 2H)
RE2	(4-Chlorophenethyl)-(4-fluorophenyl)-ketone	3.0 (t, 2H), 3.2 (t, 2H), 7.0 (dd, 2H), 7.1 (dd, 2H), 7.2 (dd, 2H), 8.0 (dd, 2H)
RE3	(2-Thien-2-ylethyl)-(4-fluorophenyl)-ketone	3.3 (m, 4H), 6.8 (d, 1H), 6.9 (dd, 1H), 7.1 (m, 3H), 8.0 (dd, 2H)
14	(2-Thien-2-ylethyl)-(4-methylphenyl)-ketone	2.4 (s, 3H), 3.3 (m, 4H), 6.8 (d, 1H), 6.9 (dd, 1H), 7.1 (dd, 1H), 7.2 (dd, 2H), 7.8 (dd, 2H)
15	(4-Chlorophenethyl)-(thiazol-2-yl)-ketone	3.0 (t, 2H), 3.5 (t, 2H), 7.2 (m, 4H), 7.6 (d, 1H), 8.0 (d, 1H)
16	(2-Thien-2-ylethyl)-(thiazol-2-yl)-ketone	3.3 (t, 2H), 3.6 (t, 2H), 6.9 (dd, 2H), 7.1 (d, 1H), 7.6 (d, 1H), 8.0 (d, 1H)

Reference Examples 4 and 5 and Examples 17-18

The following compounds were made by the procedure of J.Med.Chem.; EN; 30; 12; 1987; 2232-2239.

Ex	Compound	M/z	NMR
RE4	(Morpholinosulphonylmethyl)-(4-fluorophenyl)-ketone	286	3.3 (dd, 4H), 3.7 (dd, 4H), 4.5 (s, 2H), 7.2 (m, 2H), 8.0 (m, 2H)
17	(Piperidin-1-ylsulphonylmethyl)-(4-fluorophenyl)-ketone	284	1.6 (m, 6H), 3.3 (m, 4H), 4.5 (s, 2H), 7.2 (m, 2H), 8.0 (m, 2H)
18	[4-(4-Fluorophenyl)piperidin-1-ylsulphonylmethyl]-(4-fluorophenyl)-ketone	378	
RE5	[N-Methylanilinsulphonylmethyl]-(phenyl)-ketone	288 (M-H) ⁺	3.35 (s, 3H), 4.60 (s, 2H), 7.35 (m, 1H), 7.40 (m, 2H), 7.50 (m, 4H), 7.60 (m, 1H), 8.00 (d, 2H)

Example 19

(4-Bromophenylsulphonylmethyl)-(4-cyanophenyl)-ketone

- 5 To a stirred solution of methyl 4-cyanobenzoate (150mg, 0.93mmole) and 4-bromophenyl methyl sulphone (200mg, 0.84mmole) in 1,2-dimethoxyethane (10ml) was added NaH (40%) (120mg, 3mmol). The reaction was warmed to 85°C and stirred at this temperature for 6 hours. The reaction was allowed to cool to room temperature and then quenched with water (~50ml). The solution was transferred to a sep funnel and washed with
- 10 ether, the layers were separated and the organic layer was extracted with 1M NaOH. The aqueous layers were combined and acidified to ~pH3 with conc HCl. The resulting suspension was extracted with DCM (2x50ml), the organic layers were combined and washed with brine then dried (MgSO₄), filtered and evaporated to yield an oil. Oil purified by column chromatography (10g Si, DCM) to yield a clear oil which crystallised on standing. NMR: 4.65
- 15 (s, 2H), 7.65 (m, 4H), 7.75 (d, 2H), 8.00 (d, 2H); m/z 363 (M-H)⁺.

Examples 20-29 and Reference Example 6

The procedure described in Example 19 was repeated using the appropriate starting materials.

Ex	Compound	M/z	NMR
20	(4-Bromophenylsulphonylmethyl)-(4-trifluoromethylphenyl)-ketone	406 (M-H) ⁺	4.75 (s, 2H), 7.70 (m, 4H), 7.80 (d, 2H), 8.10 (d, 2H)
21	(4-Fluorophenylsulphonylmethyl)-(4-trifluoromethylphenyl)-ketone	345 (M-H) ⁺	4.70 (s, 2H), 7.20 (m, 2H), 7.70 (d, 2H), 7.85 (m, 2H), 8.00 (d, 2H)
22	(Thien-2-ylsulphonylmethyl)-(thien-2-yl)-ketone	271 (M-H) ⁺	4.70 (s, 2H), 7.15 (m, 2H), 7.75 (br m, 4H)
23	(Thien-2-ylsulphonylmethyl)-(4-cyanophenyl)-ketone	290 (M-H) ⁺	4.85 (s, 2H), 7.15 (m, 1H), 7.65 (m, 1H), 7.80 (m, 3H), 8.10 (d, 2H)
24	(Thien-2-ylsulphonylmethyl)-(4-trifluoromethylphenyl)-ketone	333 (M-H) ⁺	4.80 (s, 2H), 7.10 (m, 1H), 7.60 (d, 1H), 7.70 (m, 3H), 8.00 (d, 2H)
25	(4-Bromophenylsulphonylmethyl)-(thien-2-yl)-ketone	344 (M-H) ⁺	4.60 (s, 2H), 7.20 (m 1H), 7.75 (br m, 6H)
26	(4-Methylphenylsulphonylmethyl)-(4-cyanophenyl)-ketone	298 (M-H) ⁺	4.75 (s, 2H), 7.35 (d, 2H), 7.75 (m, 4H), 8.05 (d, 2H)
27	(4-Fluorophenylsulphonylmethyl)-(4-fluorophenyl)-ketone	295 (M-H) ⁺	4.65 (s, 2H), 7.20 (m, 4H), 7.90 (m, 2H), 8.00 (m, 2H)
28	(Thien-2-ylsulphonylmethyl)-(4-fluorophenyl)-ketone	283 (M-H) ⁺	4.80 (s, 2H), 7.20 (m, 3H), 7.70 (m, 2H), 8.00 (m, 2H)
29	(Thien-2-ylsulphonylmethyl)-(fur-2-yl)-ketone	255 (M-H) ⁺	4.70 (s, 2H), 6.60 (m, 1H), 7.15 (m, 1H), 7.35 (m, 1H), 7.60 (s, 1H), 7.70 (d, 1H), 7.75 (d, 1H)
RE6	(4-Methylphenylsulphonylmethyl)-(fur-2-yl)-ketone	263 (M-H) ⁺	2.45 (s, 3H), 4.55 (s, 2H), 6.60 (m, 1H), 7.35 (m, 3H), 7.60 (s, 1H), 7.80 (d, 2H)

Examples 30-31

The following compounds were made by the procedure of Syn.Lett.; EN; 10; 2000; 1500 - 1502 (except 1.2eq of NaI was added to the reaction mixture) using the appropriate 5 starting materials.

Ex	Compound	M/z	NMR (DMSO-d ₆)
30	[α -(2-Methylthiazol-4-ylmethyl)benzyl]-(phenyl)-ketone	308	2.50 (s, 3H), 3.05 (dd, 1H), 3.50 (dd, 1H), 5.35 (t, 1H), 6.95 (s, 1H), 7.15 (m, 1H), 7.25 (m, 2H), 7.35 (m, 2H), 7.45 (t, 2H), 7.55 (t, 1H), 8.00 (d, 2H)
31	[α -(2-Chlorothiazol-5-ylmethyl)benzyl]-(phenyl)-ketone	328	3.25 (dd, 1H), 3.55 (dd, 1H), 5.15 (t, 1H), 7.15 (m, 1H), 7.30 (m, 5H), 7.45 (t, 2H), 7.55 (t, 1H), 8.00 (d, 2H)

Example 32[α -(4-Methoxycarbonylbenzyl)benzyl]-(phenyl)-ketone

5 To deoxybenzoin (50 mg, 0.25 mmol) in THF (2ml) at 0°C under a nitrogen atmosphere was added dropwise a 1M solution of lithium bis(trimethylsilyl)amide in THF (0.28 ml, 0.28 mmol). The reaction was stirred at 0°C for 3 hr 30 mins before being added dropwise to a solution of methyl 4-(bromomethyl)benzoate (229 mg, 0.28 mmol) in THF (2 ml) at 0°C under a nitrogen atmosphere. The reaction was stirred in the melting ice bath for 16

10 hr. Water (5 ml) was added slowly to the reaction, which was then extracted with DCM (3x15 ml). The combined organic layers were concentrated *in vacuo*. The crude product was chromatographed on Kieselgel 60, eluting with 15% EtOAc in *iso*-hexane, to give the product as a white solid (57 mg, 66%). NMR (300MHz, DMSO-d₆) 3.05 (1H, dd), 3.45 (1H, dd), 3.80 (3H, s), 5.25 (1H, t), 7.35 (10H, m), 7.75 (2H, d), 7.95 (2H, d); m/z 345.

15

Reference Example 7 and Examples 33-43

The procedure described in Example 32 was repeated using the appropriate starting materials.

Ex	Compound	M/z	NMR (300MHz, DMSO-d ₆)
RE7 A	(α -Methylbenzyl)-(4-chlorophenyl)-ketone	245	1.40 (3H, d), 4.90 (1H, q), 7.30 (5H, m), 7.50 (2H, d), 7.95 (2H, d)
33	[α -(Benzyl)benzyl]-(5-bromothien-2-yl)-ketone	371	3.00 (1H, dd), 3.40 (1H, dd), 5.05 (1H, t), 7.25 (11H, m), 7.95 (1H, d)

34	[α -(Benzyl)benzyl]-(thien-2-yl)-ketone	293	3.00 (1H, dd), 3.40 (1H, dd), 5.05 (1H, t), 7.15 (7H, m), 7.25 (2H, t), 7.40 (2H, d), 7.90 (1H, d), 8.05 (1H, d)
35	[α -(Pyrid-3-ylmethyl)benzyl]-(phenyl)-ketone	288	3.05 (1H, dd), 3.40 (1H, dd), 5.25 (1H, t), 7.35 (10H, m), 8.00 (2H, d), 8.35 (2H, m)
36	[α -(Pyrid-2-ylmethyl)benzyl]-(phenyl)-ketone	288	3.15 (1H, dd), 3.65 (1H, dd), 5.50 (1H, dd), 7.35 (11H, m), 8.00 (2H, d), 8.35 (1H, d)
37	[α -(3-Methoxycarbonylbenzyl)benzyl]-(phenyl)-ketone	313 [M-OMe] ⁺	3.05 (1H, dd), 3.45 (1H, dd), 3.80 (3H, s), 5.25 (1H, t), 7.35 (10H, m), 7.70 (1H, d), 7.80 (1H, s), 7.95 (2H, d)
38	[α -(Pyrid-4-ylmethyl)benzyl]-(phenyl)-ketone	288	3.05 (1H, dd), 3.40 (1H, dd), 5.30 (1H, t), 7.35 (10H, m), 8.00 (2H, d), 8.35 (2H, d)
39	[α -(2-Ethoxycarbonylbenzyl)benzyl]-(phenyl)-ketone	345	1.25 (3H, t), 3.05 (1H, dd), 3.45 (1H, dd), 4.25 (2H, q), 5.25 (1H, t), 7.35 (10H, m), 7.75 (2H, d), 7.95 (2H, d)
40	[α -(2-Nitrobenzyl)benzyl]-(phenyl)-ketone	332	3.25 (1H, dd), 3.65 (1H, dd), 5.20 (1H, t), 7.35 (11H, m), 7.85 (1H, d), 7.95 (2H, d)
41	[α -(3-Nitrobenzyl)benzyl]-(phenyl)-ketone	332	3.15 (1H, dd), 3.35 (1H, dd), 5.30 (1H, t), 7.40 (10H, m), 8.00 (4H, m)
42	[α -(3-Nitro-6-methoxybenzyl)benzyl]-(phenyl)-ketone	362	3.10 (1H, dd), 3.40 (1H, dd), 3.85 (3H, s), 5.15 (1H, t), 7.15 (6H, m), 7.45 (2H, m), 7.95 (5H, m)
43	[α -(5-Nitrofur-2-ylmethyl)benzyl]-(phenyl)-ketone		3.20 (1H, dd), 3.35 (1H, dd), 5.35 (1H, t), 6.50 (1H, d), 7.35 (9H, m), 8.00 (2H, d)

^A Methyl iodide was the alkylating reagent.

Example 44

(4-Cyanophenoxymethyl)-(4-chlorophenyl)-ketone

- 5 2-Bromo-4'-chloroacetophenone (500mg, 2.15mmol), 4-cyanophenol (256.4mg, 2.15mmol) and potassium carbonate (297.4mg, 2.15mmol) were placed in acetone and the reaction mixture was stirred and heated at reflux overnight. On cooling, the solvent was evaporated in vacuo and the residue partitioned between EtOAc and water. The organic layer was separated, dried over magnesium sulphate and the organics removed in vacuo to give a
- 10 brown solid. This was triturated with a 1:1 mixture of EtOAc and hexane to give a white solid, which was collection by filtration, 327.7mg, 56%. NMR (300MHz): 5.25 (s, 2H), 6.95 (d, 2H), 7.45 (d, 2H), 7.55 (d, 2H), 7.90 (d, 2H); m/z 270 for (M-H)⁺.

Examples 45-51

- 15 The procedure described in Example 44 was repeated using the appropriate starting materials.

Ex	Compound	M/z	NMR
45	(4-Ethoxyphenoxyethyl)-(4-chlorophenyl)-ketone	291	1.30 (t, 3H), 3.90 (q, 2H), 5.05 (s, 2H), 6.75 (m, 4H), 7.40 (d, 2H), 7.85 (d, 2H)
46	(4-Phenylphenoxyethyl)-(4-chlorophenyl)-ketone	323	5.05 (s, 2H), 6.90 (d, 2H), 7.25 (t, 1H), 7.35 (t, 2H), 7.45 (m, 6H), 7.90 (d, 2H)
47	(4-Mesylphenoxyethyl)-(4-chlorophenyl)-ketone	323 (M-H) ⁺	2.95 (s, 3H), 5.25 (s, 2H), 6.95 (d, 2H), 7.45 (d, 2H), 7.80 (d, 2H), 7.85 (d, 2H)
48	(4-Fluoro-3-chlorophenoxyethyl)-(4-chlorophenyl)-ketone	297 (M-H) ⁺	5.20 (s, 2H), 6.80 (m, 1H), 6.95 – 7.05 (m, 2H), 7.50 (d, 2H), 7.90 (d, 2H)
49	(4-Fluoro-2-chlorophenoxyethyl)-(4-chlorophenyl)-ketone	297 (M-H) ⁺	5.20 (s, 2H), 6.80 (m, 2H), 7.10 (m, 1H), 7.45 (dd, 2H), 7.95 (dd, 2H)
50	(4-Cyanomethylphenoxyethyl)-(4-chlorophenyl)-ketone	286	3.70 (s, 2H), 5.20 (s, 2H), 6.90 (d, 2H), 7.20 (d, 2H), 7.50 (d, 2H), 7.90 (d, 2H)
51	[4-(2-Thiazolin-2-yl)phenoxyethyl)-(4-chlorophenyl)-ketone	332	3.40 (t, 2H), 4.40 (t, 2H), 5.25 (s, 2H), 6.90 (d, 2H), 7.50 (d, 2H), 7.75 (d, 2H), 7.95 (d, 2H)

Preparation of Starting Materials

The starting materials for the above Examples are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.

Method 1

10 N-Methoxy-N-methyl-3-thienylmethanamide

Pyridine (5.0 ml) was added to a solution of N,O-dimethylhydroxylamine hydrochloride (3.00 g, 30.88 mmol) and 2-(3-thienyl)-acetyl chloride (3.55 g, 25.0 mmol) in

DCM (100 ml) at 0°C. The resultant mixture was stirred at ambient temperature for 1 hour, washed with water (50 ml), dried and evaporated to dryness. The residue was purified by column chromatography using 30% EtOAc in hexane as eluent to give, as a liquid, N-methoxy-N-methyl-2-thienylethanamide (3.2 g, 17.3 mmol). NMR 3.2 (s, 3H), 3.6 (s, 3H),
5 3.8 (s, 2H), 7.0 (d, 1H), 7.1 (s, 1H), 7.2 (d, 1H).


Method 2

N-Methoxy-N-methyl-2-thienylethanamide

Pyridine (0.5 ml) was added to a solution of N,O-dimethylhydroxylamine
10 hydrochloride (300 mg, 3.08 mmol) and 3-(2-thienyl)-propionyl chloride (435 mg, 2.5 mmol) in DCM (10 ml) at 0°C. The resultant mixture was stirred at ambient temperature for 1 hour, washed with water (5 ml), dried and evaporated to dryness. The residue was purified by column chromatography using 30% EtOAc in hexane as eluent to give, as a liquid, N-methoxy-N-methyl-2-thienylethanamide (390 mg, 1.96 mmol); NMR: 2.8 (t, 2H), 3.2 (t, 2H),
15 3.2 (s, 3H), 3.6 (s, 3H), 6.8 (dd, 1H), 6.9 (dd, 1H), 7.1 (dd, 1H).

CLAIMS

1. The use of a compound of formula (I):



5

wherein:

Ring A is selected from aryl or heteroaryl;

R^1 is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy,

- 10 N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl) $_2$ amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl) $_2$ carbamoyl, C_{1-4} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl) $_2$ sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclyl C_{0-4} alkylene-Y- and heterocyclyl C_{0-4} alkylene-Y-; or two R^1 on adjacent carbons may form an oxy C_{1-4} alkoxy group; wherein R^1 may be optionally substituted
- 15 on carbon by one or more groups selected from R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^8 ;

n is 0-3; wherein the values of R^1 may be the same or different;

- R^2 , R^3 , R^4 and R^5 are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl) $_2$ amino, carbocyclyl, heterocyclyl,
- 20 carbocyclyl C_{1-4} alkyl, heterocyclyl C_{1-4} alkyl; wherein R^2 , R^3 , R^4 and R^5 may be independently optionally substituted on carbon by one or more groups selected from R^9 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{10} ;

- X is $-CR^{11}R^{12}$ -, $-S(O)_a$ -, $-O$ -, $-NR^{13}$ -, $-C(O)$ -, $-C(O)NR^{14}$ -, $-NR^{15}C(O)$ -, $-SO_2NR^{16}$ - or
- 25 $-NR^{16}SO_2$ -, wherein a is 0 to 2;

q is 0 or 1;

p is 0 or 1;

Ring B is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{17} ;

R^6 is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl,

5 N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC₀₋₄alkylene-Y- and heterocyclylC₀₋₄alkylene-Y-; wherein R^6 may be optionally substituted on carbon by one or more groups selected from R^{18} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a

10 group selected from R^{19} ;

m is 0-3; wherein the values of R^6 may be the same or different;

Y is -S(O)_a-, -O-, -NR²⁰-, -C(O)-, -C(O)NR²¹-, -NR²²C(O)- or -SO₂NR²³-; wherein a is 0 to 2;

R^7 , R^9 and R^{18} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl, C_{1-4} alkylsulphonylamino, carbocyclyl

15 and heterocyclyl; wherein R^7 , R^9 and R^{18} may be independently optionally substituted on carbon by one or more R^{26} ;

R^{11} and R^{12} are independently selected from hydrogen, hydroxy, amino, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, carbocyclyl, heterocyclyl carbocyclylC₁₋₄alkyl, heterocyclylC₁₋₄alkyl; wherein R^9 and R^{10} may be independently

25 optionally substituted on carbon by one or more groups selected from R^{24} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{25} ;

R^{24} is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl,

30 C_{1-4} alkoxy, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, C_{1-4} alkanoylamino, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)₂carbamoyl, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkoxycarbonyl, N -(C_{1-4} alkyl)sulphamoyl, N,N -(C_{1-4} alkyl)₂sulphamoyl and C_{1-4} alkylsulphonylamino;

R^8 , R^{10} , R^{17} , R^{19} and R^{25} are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, C_{1-4} alkoxycarbonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R^{13} , R^{14} , R^{15} , R^{16} , R^{20} , R^{21} , R^{22} and R^{23} are independently selected from hydrogen,
5 phenyl and C_{1-4} alkyl;


R^{26} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, N -methyl- N -ethylamino, acetylamino, N -methylcarbamoyl, N -ethylcarbamoyl, N,N -dimethylcarbamoyl,
10 N,N -diethylcarbamoyl, N -methyl- N -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N -methylsulphamoyl, N -ethylsulphamoyl, N,N -dimethylsulphamoyl, N,N -diethylsulphamoyl or N -methyl- N -ethylsulphamoyl;
or a pharmaceutically acceptable salt thereof;

15 in the manufacture of a medicament for use in the inhibition of 11 β HSD1.

A B S T R A C T

TITLE: CHEMICAL COMPOUNDS

5 Compounds of formula (I):



(I)

wherein variable groups are as defined within; for use in the inhibition of 11 β HSD1 are described.

10

RECEIVED OFFICE
07 AUG 2003
Received in Patents
International Unit

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.